Methods for managing prostate cancer based on PSA glycosylation

By calculating an invasiveness score by measuring specific glycoform levels in PSA, this approach addresses the shortcomings of existing PSA testing methods in prostate cancer diagnosis, achieving more accurate assessment of invasive prostate cancer and reducing overtreatment.

CN118974557APending Publication Date: 2024-11-15F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032902.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-08
Filing Date
2023-04-06
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing PSA detection methods lack sufficient sensitivity and specificity in the diagnosis of prostate cancer, making it difficult to effectively distinguish between indolent and invasive prostate cancer, leading to overdiagnosis and overtreatment. Furthermore, traditional lectin and mass spectrometry methods have limitations.

Method used

By measuring the levels of specific glycoforms of prostate-specific antigen (PSA) in biological fluids, particularly single-antennae and double-antennae PSA glycoforms, an invasiveness score is calculated to help determine whether a subject has invasive prostate cancer.

Benefits of technology

It has improved the sensitivity and specificity of prostate cancer diagnosis, reduced overdiagnosis, provided more accurate assessment of invasiveness, and reduced unnecessary treatment interventions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005073277830000491
    Figure BDA0005073277830000491
  • Figure BDA0005073277830000501
    Figure BDA0005073277830000501
  • Figure BDA0005073277830000511
    Figure BDA0005073277830000511
Patent Text Reader

Abstract

The present invention relates to a method for assessing whether a patient has aggressive prostate cancer by determining the level of a specific glycoform attached to the Prostate Specific Antigen (PSA) protein in a biological fluid sample of the subject and comparing the determined level or concentration to a reference. The methods are particularly useful for assessing subjects having a total PSA in the serum of the subject from 2 ng / ml to 10 ng / ml.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] In 2020, more than 1.4 million patients were diagnosed with prostate cancer (PCa) worldwide (Sung et al., CA Cancer J. Clin. 71: 209-249, 2021). Prostate-specific antigen (PSA) concentrations in serum are used as an early detection and prediction method for PCa; however, the test exhibits low sensitivity, specificity, and poor predictive value (Wolf et al., Ca-Cancer J. Clin. 60: 70-98, 2010). Preliminary studies have shown that glycosylation of PSA may provide promising clues for more specific PCa diagnosis. Recently, the Center for Proteomics and Metabolomics (CPM) at Leiden University Medical Center established a high-performance PSA glycomics assay (PGA), which allows for detailed glycosylation analysis, including distinguishing α2,6 sialylated isomers from α2,3 sialylated isomers ( Figure 1 ; Kammeijer et al., Anal. Chem. 90:4414-4421, 2018). Those isomers have also been implicated as potential biomarkers for aggressive cancers (Schultz et al., Cancer Metastasis Rev. 31:501-518, 2012). PGA includes a PSA affinity purification step followed by trypsin digestion and mass spectrometry (MS) analysis by capillary electrophoresis-electrospray ionization (CE-ESI) (Kammeijer et al., Anal. Chem. 90:4414-4421, 2018),

[0002] There are serious disadvantages in using PSA as a biomarker: first, PSA is not a PCa-specific biomarker because its body fluid level (usually blood) cannot effectively distinguish PCa from other prostate diseases, such as benign prostatic hyperplasia (BPH) or prostatitis (Hudson et al., JUrol.151:1291-1291, 1989). In addition, PSA serum levels are affected by multiple factors such as age, comorbidities, ejaculation, catheterization and medication (Hatekeyama et al., Int J Clin Oncol, 22:214-221, 2017). PSA distinction between PCa and benign prostate diseases is particularly inefficient in the so-called "gray area" ranging from 2ng / ml to 10ng / ml (Barry, MJ, N Engl J Med.360(13):1351-4, 2009) and in the distinction between indolent PCa and aggressive PCa (Lamy et al., Eur Urol Focus.4(6):790-803, 2018).

[0003] Screening for PCa with PSA has led to a reduction in advanced disease and disease-specific mortality. However, the cost is overdiagnosis of cases that would not have clinical consequences in a man's lifetime even if not treated in time. Overdiagnosis has led to overtreatment, with significant risks, such as side effects from biopsy or negative consequences of treatment (Loeb et al., Eur Urol, 65(6): 1046–1055, 2014). According to www.uspreventiveservicestaskforce.org (FinalRecommendation Statement: Screening for Prostate Cancer and FinalEvidenceReview: Screening for Prostate Cancer.USPreventive Services Task Force. May 2018. www.uspreventiveservicestaskforce.org), 20% to 50% of diagnosed men have an indolent, non-threatening form of PCa. These data clearly demonstrate the major problem of overdiagnosis and the need for improved, more specific PCa diagnostics and cancer aggressiveness assessment tools.

[0004] The single N-linked glycosylation site (N 69 ) is occupied by very heterogeneous groups of glycans, resulting in a variety of so-called glycoforms with the same protein backbone. Previous studies have speculated that detailed analysis of PSA glycoforms may provide more effective PCa diagnosis (Vermassen et al. (supra); Jankovic et al., Clin. Biochem. 38:58-65, 2005; Peracaula et al., Glycobiology. 13:457-470, 2003); Saldova et al., Glycobiology. 21:195-205, 2011). Subsequent studies on molecular features of PSA glycosylation, such as antennae modifications and core fucosylation, also showed that PCa diagnosis was improved by combining traditional PSA testing with specific N-glycan features (Kyselova et al. J. Proteome Res. 6: 1822-1832, 2007; Vermassen et al. Electrophoresis. 35: 1017-1024, 2014; Yoneyama et al., Biochem. Biophys. Res. Commun. 448: 390-396, 2014), however, the size of the test cohort is limited and there is still a great need to identify new diol structures. In addition, there is a need to identify biomarkers for assessing PCa aggressiveness.

[0005] Currently, methods based on lectins or mass spectrometry are used to detect PSA glycoforms (Llop et al., Theranostics. 6(8): 1190-204, 2016; Kuzmanov et al., BMC Med. 11: 31, 2013). The limitation of the application of lectins is that they are only reactive to sugar residues, not to protein backbones. In addition, lectins have low specificity in resolving related glycan structures, and their reactivity is mainly based on high affinity rather than affinity. On the other hand, mass spectrometry requires more purification steps, especially in the case of complex matrices (such as serum or plasma). Summary of the invention

[0006] The inventors have demonstrated that prostate-specific antigen (PSA) secreted from prostate cells into biological fluids (such as blood and urine) is glycosylated to varying degrees, and surprisingly found that the levels of specific PSA glycoforms are increased, while the levels of other PSA glycoforms are reduced in subjects with aggressive forms of PCa. The present invention relies on these changes in the levels of one or more specific PSA glycoforms to detect whether a subject has or is likely to have an aggressive form of PCa. Therefore, the method of the present invention can be used to determine whether a subject suffering from or suspected of having a prostate disease (which can be any form of PCa or non-cancerous prostate disease, such as prostatitis or BPH) is likely to have an indolent disease or aggressive PCa. This characterization can then be used to provide information for the next treatment or analytical intervention. For example, individuals determined to be likely to have aggressive PCa can be selected for biopsy and / or therapeutic treatment. Individuals determined to be likely not to have aggressive PCa can be selected for "watchful waiting", i.e., regular monitoring but no (direct) intervention.

[0007] According to a first aspect of the present invention, there is provided a method for assisting in determining whether a subject has an aggressive form of prostate cancer, the method comprising:

[0008] (a) determining the level of at least one monoantennary PSA glycoform and the level of at least one biantennary PSA glycoform in a biological fluid sample from a subject;

[0009] (b) calculating an aggressiveness score for the subject using the levels determined in (a);

[0010] (c) comparing the aggressiveness score of the subject in (b) with a reference value for the aggressiveness score; and

[0011] (d) using the comparison in (c) to help determine whether the subject has an aggressive form of prostate cancer.

[0012] According to a second aspect of the present invention, there is provided a method for determining whether a subject suffers from an aggressive form of prostate cancer, the method comprising:

[0013] (i) separating PSA protein from other proteins in a biological fluid sample from a subject;

[0014] (ii) treating the separated PSA protein with a protease;

[0015] (iii) Determine the presence of two or more N 69 The level of each of the glycopeptide forms, where N 69 At least one of the glycopeptide forms is a monoantennary glycoform and N 69 At least one of the glycopeptide forms is a biantennary glycoform;

[0016] (iv) Using each N in (iii) 69 The level of glycopeptide forms was used to determine the aggressiveness score for the subject;

[0017] (v) comparing the aggressiveness score in (iv) with a reference value for the aggressiveness score; and

[0018] (vi) determining whether the subject has an aggressive form of PCa based on the comparison in step (v).

[0019] In certain embodiments, the level determined in step (iii) is a normalized level.In certain embodiments, the PSA protein is isolated from a biological fluid sample from a subject using a binding protein (such as an antibody) specific for the PSA protein.

[0020] In certain embodiments, the level of a PSA glycoform corresponds to a PSA glycoform (e.g., N 69 The normalized amount of a glycopeptide (glycopeptide) relative to the sum of the amounts of all measured PSA glycoforms (e.g., all glycoforms shown in Table 1A).

[0021] In certain embodiments, the level of a PSA glycoform corresponds to a level of a PSA glycoform (e.g., N 69 In certain embodiments, a normalized signal (e.g., area under the curve) related to the amount of PSA glycopeptide (e.g., glycopeptide) is normalized to the signal of all measured PSA glycoforms (e.g., all glycoforms shown in Table 1A). In certain embodiments, a binding protein (e.g., an antibody) specific for the PSA protein is used to separate / isolate the PSA protein from other components (e.g., other antibodies) in the biological fluid sample.

[0022] It should be understood that the isolated PSA protein may contain a variety of different proteoglycan species (PSA glycoforms). Proteases are used to digest the PSA protein into smaller peptide forms, allowing the various proteoglycan species to be attached to the smaller peptides. A suitable protease is trypsin, which will produce N 69 Another suitable protease is Arg-C (clostripain), which will generate N 69 KSVILLGR (SEQ ID NO: 3) proteoglycan population.

[0023] In a specific embodiment, an aggressiveness score is determined for the first aspect of the invention. In a specific embodiment, a reference aggressiveness score is determined for the first aspect of the invention.

[0024] The first and second aspects of the present invention relate to the measurement of the levels of at least two PSA glycoforms. However, as can be seen from Table 6, the levels of three PSA glycoforms (compounds 21, 2 and 9) are able to better distinguish aggressive PCa from indolent PCa and BPH than free PSA (higher area under the curve (AUC) in receiver operating characteristic (ROC) analysis). Therefore, the level of each of these three PSA glycoforms can be used alone to assist in determining whether a subject has aggressive PCa.

[0025] Therefore, according to a third aspect of the present invention, there is provided a method for assisting in determining whether a subject has an aggressive form of prostate cancer, the method comprising:

[0026] (a) determining the level of a PSA glycoform selected from the group consisting of: H4N5F1S in a biological fluid sample from a subject 2,3 1S 2,6 1;H4N3S 2,6 1; and H5N4F1S 26 1;

[0027] (b) comparing the value for the PSA glycoform level in (a) with a reference value for the PSA glycoform; or comparing the aggressiveness score taking into account the PSA glycoform level in (a) with a reference value for the aggressiveness score; and

[0028] (c) using the comparison in (b) to help determine whether the subject has an aggressive form of prostate cancer.

[0029] According to a fourth aspect of the present invention, there is provided a computer-implemented method for assisting in determining whether a subject has an aggressive form of prostate cancer, the method comprising the steps of:

[0030] (a) receiving a value for the level of a first monoantennary PSA glycoform in a biological fluid sample of a subject;

[0031] (b) receiving a value for the level of a first biantennary PSA glycoform in a biological fluid sample of the subject;

[0032] (c) calculating an aggressiveness score for the subject based on the levels received in (a) and (b);

[0033] (d) comparing the aggressiveness score of the subject in (c) with a reference value of the aggressiveness score; and

[0034] (e) using the comparison in (d) to help determine whether the subject has an aggressive form of prostate cancer.

[0035] In certain embodiments, the first monoantennary PSA glycoform of step (a) is selected from Compound 2, 3, 4 or 5 (as shown in Tables 1A and 1B).

[0036] In certain embodiments, the first biantennary PSA glycoform of step (b) is selected from compound 7, 9, 10, 11, 13, 16, 18, 21, 24 or 25 (as shown in Tables 1A and 1B).

[0037] In certain embodiments, the invasiveness score in step (c) is calculated by combining the levels received in steps (a) and (b). In certain embodiments, the invasiveness score in step (c) is calculated by introducing the levels received in steps (a) and (b) into an equation (e.g., a weighted calculation matrix, a ratio, etc.).

[0038] The values ​​received in (a) and (b) may be obtained from the PSA glycoforms determined in the first aspect of the invention. The embodiments suitable for the first aspect of the invention may be applied to this fourth aspect of the invention where appropriate.

[0039] According to a fifth aspect of the present invention, there is provided a computer-implemented method for assisting in determining whether a subject has an aggressive form of PCa, the method comprising the following steps:

[0040] (a) receiving a value in a biological fluid sample of a subject for the level of a PSA glycoform selected from the group consisting of: H4N5F1S 2,3 1S 2,6 1;H4N3S 2,6 1; and H5N4F1S 2,6 1;

[0041] (b) comparing the value for the PSA glycoform level received in (a) with a reference value for the PSA glycoform; or comparing the aggressiveness score taking into account the PSA glycoform level received in (a) with a reference value for the aggressiveness score; and

[0042] (c) using the comparison in (b) to help determine whether the subject has an aggressive form of prostate cancer.

[0043] In a particular embodiment of the fifth aspect of the present invention, there is provided a computer-implemented method for assisting in determining whether a subject has an aggressive form of prostate cancer, the method comprising the steps of:

[0044] (a) receiving a value in a biological fluid sample of a subject for the level of a PSA glycoform selected from the group consisting of: H4N5F1S 2,3 1S 2,6 1;H4N3S 2,6 1; and H5N4F1S 2,6 1;

[0045] (b) comparing the value for the level of a PSA glycoform received in (a) with a reference value for the PSA glycoform; and

[0046] (c) using the comparison in (b) to help determine whether the subject has an aggressive form of prostate cancer.

[0047] The value received in (a) may be obtained from the PSA glycoform determined in the third aspect of the invention. The embodiments suitable for the third aspect of the invention may be applied to this fifth aspect of the invention where appropriate.

[0048] Suitably, the monoantennary PSA glycoform for use in the methods according to the first, second, fourth and fifth aspects of the invention is selected from one or more of compounds 2, 3, 4 and 5, as identified in Tables 1A and 1B.

[0049] Suitably, the biantennary PSA glycoform for use in the methods according to the first, second, fourth and fifth aspects of the invention is selected from one or more of compounds 7, 9, 10, 11, 13, 16, 18, 21, 24 and 25, as identified in Tables 1A and 1B.

[0050] The methods of the first, second, third, fourth and fifth aspects of the invention can be used to assist in determining whether a subject has an aggressive form of PCa or to assist in determining whether a subject does not have an aggressive form of PCa, such as indolent prostate disease. Suitably, the methods of the first, second, third, fourth or fifth aspects of the invention can be used to assist in determining whether a subject has an indolent prostate disease, such as BPH.

[0051] According to a sixth aspect of the present invention, there is provided a kit (or use of a kit) for use in or with a method according to the first, second, third, fourth or fifth aspect of the present invention, the kit comprising a prostate cancer aggressiveness score or scoring system (e.g., a determination system having a PSA glycoform threshold indicating aggressive PCa). Optionally, the kit further comprises a PSA protein binder, such as a monoclonal antibody. Such PSA protein binders can be used to separate or purify PSA protein. In an embodiment, the kit may include a protease. The protease can be used to generate a PSA glycopeptide that can be measured via mass spectrometry. In an embodiment, the kit may be a kit for mass spectrometry detection of PSA glycoforms. DETAILED DESCRIPTION

[0052] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. Although methods and materials similar or equivalent to those described herein may be used in the practice or testing of the present invention, suitable methods and materials are described below. In the event of ambiguity, this patent specification (including definitions) shall prevail. In addition, materials, methods and examples are illustrative only and are not intended to be limiting.

[0053] The disclosed methods may be more readily understood by reference to the following detailed description, which forms a part of the present disclosure. It should be understood that the disclosed methods are not limited to the specific methods described and / or illustrated herein, and that the terminology used herein is only for the purpose of describing specific embodiments by way of example and is not intended to limit the claimed methods.

[0054] Unless otherwise indicated, the methods of the present disclosure will employ conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, and biochemistry, which are within the technical scope of the art. Exemplary techniques are fully explained in the following literature, such as "Molecular Cloning: A Laboratory Manual", 2nd edition (Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989); "Current Protocols in Molecular Biology" (FM Ausubel et al., ed., Current Protocols of Molecular Biology, John Wiley and Sons (1987); and "PCR: The Polymerase Chain Reaction" (Mullis et al., ed., Boston, 1994).

[0055] It should be understood that, for clarity, certain features of the disclosed method described herein in the context of independent embodiments may also be provided in combination in a single embodiment. Conversely, for brevity, various features of the disclosed method described in the context of a single embodiment may also be provided separately or in any sub-combination.

[0056] In describing the present invention, the following terminology will be employed and is intended to be defined as shown below.

[0057] As used in this specification and the appended claims, the singular forms "a", "an", "the" and "said" include plural referents unless the content clearly dictates otherwise. As used herein, the term "PSA glycoform species" in "species" may be singular or plural, depending on the context.

[0058] The use of alternatives (eg, "or") should be understood to mean either, both, or any combination of the alternatives.

[0059] The term "and / or" should be understood to mean either or both of the alternatives.

[0060] As used herein and unless otherwise specified, it should be understood that the term "about" is used synonymously with the term "approximately". Illustratively and unless otherwise specified, the use of the term "about" when used in conjunction with a stated value or range means slightly more or slightly less than the stated value or range, within ±15% of the stated value, within ±10% of the stated value, within ±5% of the stated value, or conveniently within ±2% of the stated value. Such values ​​are therefore encompassed by the scope of the claims reciting the term "about" or "approximately".

[0061] The word "comprise" and variations such as "comprising" and "including" will be understood to imply the inclusion of stated integers or steps or groups of integers or steps but not the exclusion of any other integers or steps or groups of integers or steps.

[0062] The term "analyte" refers to the molecule (eg, a PSA glycoform or protein) that is detected and measured.

[0063] As used herein, the term "level" or "amount" encompasses the absolute level or amount of a biomarker (e.g., a PSA glycoform) referred to herein, the normalized amount, relative amount or concentration of the biomarker (e.g., the normalized signal (e.g., area under the curve) of a biomarker (e.g., a PSA glycoform) relative to the total signal of all integrated or measured PSA glycoforms (e.g., if 5 PSA glycoforms are measured, the level can be the amount or area under the curve of PSA glycoform 1 divided by the equivalent measurement of PSA glycoforms 1+2+3+4+5; see also Table 1A)), as well as any value or parameter related thereto or derivable therefrom. Such values ​​or parameters may include integrated area values ​​or intensity signals from all specific physical or chemical properties obtained from the biomarker by direct measurement, for example, intensity values ​​in a mass spectrometer. In addition, all values ​​or parameters obtained by indirect measurement specified elsewhere in this specification are encompassed. It should be understood that values ​​related to the aforementioned PSA glycoform or parameter levels can also be obtained by all standard mathematical operations.

[0064] In certain embodiments, the level of a PSA glycoform can correspond to a PSA glycoform (e.g., N 69 The normalized amount of a glycopeptide (glycopeptide) relative to the sum of the amounts of all measured PSA glycoforms (e.g., all glycoforms shown in Table 1A).

[0065] In certain embodiments, the level of a PSA glycoform corresponds to a level of a PSA glycoform (e.g., N 69 The normalized signal (eg, area under the curve) related to the amount of PSA glycopeptide (eg, glycopeptide) is normalized to the signals of all measured PSA glycoforms (eg, all glycoforms shown in Table 1A).

[0066] The level of a PSA glycoform can be used directly for comparison with a reference value, or can be combined with the level of one or more other PSA glycoforms, for example as an aggressiveness score based on a ratio or percentage of the level of one or more other PSA glycoforms, for example, where the level of one or more other PSA glycoforms also has some biochemical significance for the target clinical condition. For example, the level of a monoantennary glycoform can be combined with the level of a biantennary glycan species to produce a ratio level. Alternatively, the levels of two or more PSA glycoforms can be introduced into an equation to produce a score that is or can be used to generate a PCa aggressiveness score (aggressive score herein).

[0067] As used herein, the term "assessment" refers to assessing or clarifying whether a subject suffers from a particular condition, e.g., whether he or she has aggressive PCa. Thus, assessment as used herein includes work to determine or identify whether a subject may have aggressive PCa and / or whether a subject may have indolent prostate disease.

[0068] As will be appreciated by those skilled in the art, although the assessment made according to the present invention is preferred, it may not be correct for 100% of the subjects studied. The term generally requires the ability to correctly assess a statistically significant portion of subjects. Those skilled in the art can use various well-known statistical evaluation tools (e.g., determining confidence intervals, determining p-values, Student's t-tests, Mann-Whitney tests, etc.) to effortlessly determine whether a portion is statistically significant. For detailed information, see Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York 1983. The confidence intervals generally envisioned are at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%. The p-value is typically 0.2, 0.1, 0.05.

[0069] As used herein, the term aggressiveness score refers to a score, e.g., a numerical score, associated with the degree of PCa aggressiveness in a sample. It is generally determined by any mathematical combination of the determined levels, optionally including other biomarkers and / or clinical information. Suitably, by comparing the score with a reference value for the aggressiveness score indicating a certain degree of aggressiveness, the score can distinguish aggressive PCa from indolent prostate disease, etc. The reference aggressiveness score can be a threshold value, so that any test score falling on one side or the other side of the value (depending on how to calibrate the score, e.g., whether a high or low score means more aggressiveness) identifies or can assist in identifying whether a subject may suffer from an aggressive form of PCa. The aggressiveness score is determined by considering the combined level of the determined PSA glycoforms. As used herein, "by considering the combined level of the determined PSA glycoforms" means using the level of each determined PSA glycoform (from a test subject, a control sample, or a historical control sample, as the case may be) in an equation involving each determined PSA glycoform level to generate a score that can be an aggressiveness score. For example, this may be the total / sum of the individual levels (so, for example, aggressiveness score = level of PSA glycoform 1 + level of PSA glycoform 2, such that the level of x for PSA glycoform 1 and the level of y for PSA glycoform 2 in the subject's biological "test" sample gives a combined level of x+y); alternatively, this may be, for example, a ratio of PSA glycoform 1 / PSA glycoform 2 (= x / y in the above example); or, for example, a ratio of PSA glycoform 2 / PSA glycoform 1 (= y / x in the above example). Alternatively, this may be some other equation involving the level of each PSA glycoform determined (for example, if the equation is: aggressiveness score = 2.5×PSA glycoform 1+1.5×PSA glycoform 2, then using the above x and y values ​​will give an aggressiveness score for the test subject of 2.5x+1.5y). The appropriate equation for use in determining the aggressiveness score using any particular combination of PSA glycoforms can be determined using standard statistical analysis of appropriate reference samples.

[0070] For use in the methods of the present invention, the level or aggressiveness score of one or more PSA glycoforms in a subject sample (test sample) will be compared with a corresponding reference value that can distinguish subjects with aggressive PCa from subjects without aggressive PCa. The reference value can be based on a method for calculating the level or aggressiveness score of the same PSA glycoform as the determined level or aggressiveness score. Such reference values ​​can be referred to as reference values ​​for aggressiveness scores, and as described herein, such reference values ​​for aggressiveness scores can be determined by comparing the levels of measured PSA glycoforms observed in individuals with aggressive forms of PCa and / or not suffering from aggressive forms of PCa.

[0071] For example, the level of a PSA glycoform measured in a test sample of a subject (alone or when combined with the level of one or more other PSA glycoforms in an appropriate equation to give an aggressiveness score) can be compared to values ​​known to be associated with aggressive PCa and / or known to be associated with individuals who do not have aggressive PCa. Typically, the level in the test sample is directly or indirectly correlated with the PCa aggressiveness state, and the marker level is used, for example, to determine whether an individual is likely to have aggressive PCa.

[0072] In the context of the present invention, an aggressiveness score can be calculated by mathematically combining various parameters (including or consisting of determined or received PSA glycoform levels). These levels can be used as is or can be mathematically transformed (e.g., by logarithmic transformation, such as log2 or log 10 transformation) to determine the score. The score can take into account one or more other factors besides the PSA glycoform level, including but not limited to the presence or level of one or more other biomarkers in the sample and / or one or more clinical parameters of the subject (e.g., tumor histology, smoking status, disease stage and / or age).

[0073] In certain embodiments of the invention, the aggressiveness score can be obtained by a weighted calculation of the levels of biomarker molecules (e.g., PSA glycoforms) in the sample. This means that certain markers can be given different weights than other markers. For example, when the score considers the level of a PSA glycoform (e.g., a monoantennary compound 2) and the level of another PSA glycoform (e.g., a biantennary compound 9) in the sample, the score can be calculated by the following equation:

[0074] Score = a*[compound 2]+b*[compound 9], wherein a and b represent weighting factors. Preferably, the weighting factors or coefficients (a and b in the above examples) have been obtained by analyzing a reference population (e.g., any reference population defined in the context of the reference values ​​below). In an embodiment, the weighting factors or coefficients can be obtained by applying a machine learning method to a training data set obtained from a sample of a reference population as defined herein in the context of reference values ​​and / or control samples.

[0075] Those skilled in the art will appreciate that the aggressiveness score and corresponding reference value for the score may be optimized based on a reference population (eg, any population as defined below in the context of determination of cutoff values).

[0076] In an embodiment of the present invention, the aggressiveness score may include or consist of the following items: the ratio of the level of at least one biantennary PSA glycoform to the level of at least one monoantennary PSA glycoform from a subject sample, or the ratio of the level of at least one monoantennary PSA glycoform to the level of at least one biantennary PSA glycoform from a subject sample.

[0077] In an embodiment where two or more monoantennary or biantennary PSA glycoforms are determined, the sum of the levels of all corresponding monoantennary or biantennary can be generated and used as a value for a ratio. The ratio is the ratio of the sum of the levels of one class of PSA glycoforms to the sum of the levels of another class of PSA glycoforms, wherein, for example, the PSA glycoform category includes monoantennary forms and biantennary forms. For example, the ratio can be composed of the ratio of all measured biantennary species to all measured monoantennary species, for example, (A+B) / C (where A and B are the levels of different biantennary species, and C is the level of a single monoantennary species; or (A+B) / (C+D), where D is a second monoantennary species). Similarly, if the ratio is the ratio of all measured monoantennary species to all measured biantennary species, it can be C / (A+B) or (C+D) / (A+B). The ratio can then be used to determine whether PCa is aggressive PCa.

[0078] Thus, in embodiments where two or more mono- or bi-antennary PSA glycoforms are identified, the sum of the corresponding mono- or bi-antennary levels will be calculated and used as the value for the ratio.

[0079] In one embodiment, the aggressiveness score can be a binary score, and the corresponding reference value can also be binary. "Binary" means that the score contains two values, for example, the first value is the level of one or more biantennary PSA glycoforms determined or received or a value derived therefrom, and the second value is the level of one or more monoantennary PSA glycoforms or a value derived therefrom. The "value derived therefrom" can, for example, be a value obtained by a mathematical operation. The "value derived therefrom" is preferably proportional to the corresponding level. For each PSA glycoform, the value of the binary reference value can be obtained as described below.

[0080] Comparing a binary score to a cutoff binary score means comparing a first value of a determined binary score to a first value of a reference value of a binary score and a second value of a determined binary score to a second value of a reference value of a binary score. In an embodiment, the aggressiveness score is a binary score that includes a first value corresponding to the level of at least one monoantennary PSA glycoform and a second value corresponding to the level of at least one biantennary PSA glycoform, and the reference value for the aggressiveness score includes a reference value for the first value and a reference value for the second value. In these embodiments, if the level of at least one monoantennary PSA glycoform (i.e., the first value of the binary score) is reduced compared to the reference value for the first value, and the level of at least one biantennary PSA glycoform (i.e., the second value of the binary score) is increased compared to the reference value for the second value, then the subject is determined to have an aggressive form of PCa. Vice versa, if only one of the first and second values ​​of such a binary score meets the aggressiveness criteria or neither meets the aggressiveness criteria, then the subject is determined to have non-aggressive prostate disease.

[0081] As used herein, the term "comparison" has its usual meaning, for example, the act of checking things to determine whether they are similar or different. In the context of the present invention, it includes comparing the level of PSA glycoforms in a sample from a subject with a reference level of PSA glycoforms, or, for example, comparing a calculated invasiveness score (e.g., based on a mathematical combination of various PSA glycoform levels measured using, for example, weighted calculations, calculations of overall (e.g., summation) levels, or construction ratios) with a reference value for such invasiveness score. It should be understood that comparisons as used herein generally refer to comparisons of corresponding parameters, values, or scores, for example, comparing an absolute amount with an absolute reference amount while comparing a concentration with a reference concentration, or comparing an intensity signal of a biomarker obtained from a sample with an intensity signal of the same type obtained from a reference sample, or comparing a collated value (e.g., an invasiveness score) obtained by inputting the level values ​​of multiple biomarkers (e.g., PSA glycoforms) into an equation with a reference value for a collated level from the same biomarker (e.g., obtained from a reference control sample or a reference cohort). As described herein, reference values ​​can also be obtained from multiple controls or reference samples, for example, obtained from a reference cohort with a known prostate (cancer) disease state (e.g., Gleason score). Comparisons can be made manually or computer-assisted. Therefore, comparisons can be made by a computing device. For example, the value of the measurement or detection level of a biomarker in a sample from a subject can be compared with a reference level, and the comparison can be automatically performed by a computer program that performs a comparison algorithm. The computer program that performs the assessment will provide the required assessment in an appropriate output format. For computer-assisted comparisons, the value of the measured level can be compared with the value corresponding to a suitable reference stored in a database by a computer program. The computer program can further evaluate the results of the comparison, i.e., automatically provide the required assessment in an appropriate output format. For computer-assisted comparisons, the value of the measured level can be compared with the value corresponding to a suitable reference stored in a database by a computer program. The computer program can further evaluate the results of the comparison, i.e., automatically provide the required assessment in an appropriate output format.

[0082] As used herein, the term "reference value" refers to a known (e.g., predetermined) value that can be compared to a test value, and is therefore a value that distinguishes between two states (e.g., yes, no; disease / healthy; aggressive PCa / non-aggressive PCa). There are essentially two alternatives for determining a reference value: 1) a control sample (which can be an internal or external sample or sample pool); 2) multiple samples from a reference population with a known disease state (e.g., aggressive PCa and / or indolent prostate disease).

[0083] Suitably, reference values ​​can be determined from one or more control samples, which are analyzed and determined in a manner substantially identical to the target test sample, or have been analyzed and determined in this manner, and their information is compared with the information of the target test sample. In one embodiment, the control sample is obtained from a control subject who does not suffer from aggressive PCa. In another embodiment, the control sample is obtained from a subject suffering from an inert prostate disease such as inert (slow-growing) PCa or BPH. In another embodiment, the control sample is obtained from a control subject suffering from an aggressive form of PCa.

[0084] The control sample can be evaluated substantially simultaneously with the test sample, and therefore can be used as a direct contemporaneous comparator, or they can be from historical samples. Therefore, the reference value can be determined or predetermined together with the value of the test sample (simultaneously). Preferably, the predetermined reference value. The value from one or more control samples thus provides a standard for allowing the evaluation of the information obtained from the target sample (test sample). In a specific embodiment, the control sample is the same sample type as the target sample. For example, if the target sample is urine, the control sample can be urine. The control sample can be derived from the body fluid obtained from a healthy individual, particularly urine, serum or plasma for non-invasive testing, so as to provide the standard of health or limited disease state of tissue, organ or individual. Alternatively, the control sample can be obtained from at least one individual suffering from aggressive PCa from the same species, such as an individual suffering from cancer with a Gleason score ≥ 7. Alternatively, the control sample can be obtained from at least one individual not suffering from aggressive PCa from the same species, or obtained from at least one individual suffering from non-cancerous prostate disease (such as BPH or prostatitis) from the same species. In a specific embodiment, the control sample can be from an individual with benign PCa with a Gleason score of <7. The individual can be the same age as the subject from which the test sample is obtained or in the same health state or condition. The difference between the state of the control sample and the state of the target test sample can indicate the existence of the disease or the risk of disease development or the existence or further progress of such diseases or illnesses. The control sample can be derived from abnormal or diseased tissue, organ, body fluid or individual (e.g., tissue, organ, body fluid or individual suffering from inert prostate disease), so as to provide a standard for the diseased state of tissue, organ or individual. The difference between the state of the abnormal reference sample and the state of the target sample can indicate PCa aggressiveness. The reference sample can also be derived from the same tissue, organ, body fluid or individual as the target sample, but has been obtained at an earlier time point. The difference between the state of the reference sample obtained earlier and the state of the target sample can indicate the progression of the disease, i.e., the disease improves or worsens over time.

[0085] The control sample can be an internal or external control sample. With an internal control sample, the marker level is assessed in the test sample and one or more other samples taken from the same subject to determine whether there is any change in the level of the marker. For an external control sample, the level of the marker in a sample derived from an individual is compared with its level in an individual known to suffer from a given condition or known to be at risk of suffering from a given condition or known to be free of a given condition (i.e., a "normal individual").

[0086] Those skilled in the art will appreciate that such external control samples can be obtained from a single individual or can be obtained from an age-matched reference population. Typically, samples from 100 well-characterized individuals from an appropriate reference population are used to establish a "reference value." However, a reference population consisting of, for example, 20, 30, 50, 200, 500, or 1000 individuals can also be selected.

[0087] Therefore, alternatively, reference value can be determined based on the sample obtained from the reference population (for example, the sample of the reference population with known prostate disease and PCa aggressiveness state). The technician can establish the reference value for PSA glycoform level or the reference value for aggressiveness score based on the representative reference population. Using the reference population, the reference value can be determined so that the level or score value set as the reference value is divided into aggressive PCa and inert prostate disease with certain sensitivity and specificity by the reference population. The reference value can be selected differently according to whether it is desired to obtain higher sensitivity at the expense of lower specificity or vice versa. The level or score separation (for example, the level or score separation of aggressive PCa and non-aggressive PCa) can be determined using known statistical methods, so as to define the desired sensitivity and specificity. The reference value for comparison with the test sample can be the mean value or median value calculated as more than one (for example, two or more, five or more, ten or more, one group, etc.) control sample. Alternatively, the control sample can be a sample derived from more than one (eg, two or more, five or more, ten or more, a group, etc.) individuals who do not have PCa (or have BPH).

[0088] Reference values ​​are typically determined based on a statistical assessment of biomarker readings / levels from multiple (e.g., >49, >99, >249, >499, >999) samples of subjects with or without a specific state to be determined (e.g., aggressive PCa) (e.g., from a reference population). A reference value can be a value for the level of a single biomarker (i.e., a separate PSA glycoform) or an aggressiveness score value derived from a separate level of a biomarker combination (i.e., two or more PSA glycoforms, as described herein), which can have been applied to an algorithm or equation to give a reference value that can be used when measuring and relying on the specific combination of biomarkers (e.g., a combination of PSA glycoforms). Typically, a reference value reaches a specific statistical threshold of significance, such as a statistical threshold of significance for a quantile in a case or control distribution. For example, in order to determine a reference value from a control cohort (BPH or indolent PCa), a percentile (e.g., 90%, 95%, 95.7%, or 97%) can be determined based on the measured values ​​of the control cohort. For example, when the 90th percentile is used, then 90% of the control samples have values ​​below this cutoff, which reduces the number of false positive predictions.

[0089] In one example, the reference value is the mean or median level of one or more PSA glycoforms taken from a group of individuals or a population of individuals with aggressive PCa from the same species. In one example, the reference value is the mean or median level taken from a group of individuals or a population of individuals who do not have PCa. For example, the reference value can be calculated as the mean or median level taken from a group of individuals or a population of individuals with aggressive PCa and / or indolent prostate disease (such as indolent PCa and / or BPH and / or prostatitis). The individual or population of individuals can be the same age or in the same health state or condition as the subject from whom the test sample is obtained.

[0090] In a specific embodiment, the reference population for establishing a reference value (e.g., a reference value for a PSA glycoform level or an aggressiveness score) is derived from a healthy individual. In another embodiment, the reference population may contain healthy individuals and individuals suffering from non-invasive and aggressive forms of PCa. In another embodiment, the reference population may include individuals suffering from non-invasive (BPH and / or inertia) and aggressive PCa. In another embodiment, the reference population may include individuals suffering from inert prostate disease. In another embodiment, the reference population may be the reference population used in the example. Preferably, the reference value in each of these embodiments is a predetermined reference value established according to a historical control sample, for example, a predetermined reference value derived from a reference population.

[0091] The reference value can also be a reference value for an aggressiveness score (if an aggressiveness score is determined) generated from the measurement of the level of two or more PSA glycoforms; the reference value is again from a group of individuals or a group of individuals with a known PCa status. Such levels can be input into an equation to generate a score (e.g., an aggressiveness score). The equation can be a ratio or a total (e.g., a sum) or any other equation, wherein the level of each PSA glycoform measured is used in the equation and wherein the output provides a score / value that distinguishes whether an individual belongs to a specific category (e.g., may have aggressive PCa, may not have aggressive PCa).

[0092] As used herein, an individual or subject "not suffering from PCa" is an individual or subject with prostate tissue that shows normal histology. Methods for histologically testing prostate tissue and identifying whether an individual has prostate tissue that shows normal histology are well known in the art, see, for example, Litwin MS and Tan HJ., The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. June 27, 2017; 317 (24): 2532-254. Therefore, in this context, a control sample obtained from an individual not suffering from PCa refers to a biological fluid sample (e.g., blood or urine sample, as the case may be) obtained from an individual of the same species, wherein the individual has prostate tissue that shows normal histology. Examples of individuals not suffering from PCa include individuals suffering from BPH, prostatitis and / or prostatic hypertrophy.

[0093] Benign prostatic hyperplasia (BPH; also called benign prostatic hypertrophy) is a medical condition that commonly affects men over the age of 50. It is a condition that can affect the way urine is excreted, but it is not cancer and does not lead to an increased risk of developing PCa.

[0094] Therefore, as used herein, an individual / subject / patient suffering from "benign prostatic hyperplasia" or "BPH" is an individual / subject / patient with an enlarged prostate and a prostate tissue that is normal in histological appearance. Methods for histologically testing prostate tissue and identifying whether an individual suffers from BPH are well known in the art, see, for example, Chughtai et al. Benign prostatic hyperplasia. Nat Rev Dis Primers. May 5, 2016; 2: 16031. Therefore, in this context, a control sample obtained from an individual suffering from BPH refers to a biological fluid sample (e.g., a blood or urine sample, as the case may be) obtained from an individual of the same species, wherein the individual has an enlarged prostate and a prostate tissue that is normal in histological appearance.

[0095] Prostatitis is the name for a group of symptoms thought to be caused by infection or inflammation of the prostate gland. Prostatitis is not a form of PCa. It is a common condition that can affect men of any age, but is most common in young and middle-aged men, usually between the ages of 30 and 50. Prostatitis can cause a variety of symptoms that vary from person to person. Common symptoms include difficulty urinating and pain or discomfort around the testicles, rectum, or lower abdomen. There are four types of prostatitis: chronic pelvic pain syndrome (CPPS), acute bacterial prostatitis, chronic bacterial prostatitis, and asymptomatic prostatitis.

[0096] Thus, a control sample obtained from a "subject suffering from prostatitis" refers to a biological fluid sample (eg, a blood or urine sample, as appropriate) that has been obtained from an individual of the same species, wherein the individual has been diagnosed with one of the above-mentioned forms of prostatitis.

[0097] An enlarged prostate is an increase in the size of the prostate gland that is not caused by cancer. The medical term for an enlarged prostate is benign prostatic hypertrophy (BPE). It is also called benign prostatic hyperplasia (BPH), which is described in more detail above.

[0098] The terms "measurement" or "measuring" or "determining" in the context of analysis preferably include qualitative, semi-quantitative or quantitative measurements. The term "determining" is also used in the context of making a decision about the status of a subject, for example identifying whether they have aggressive PCa. In this article, the term "identifying" may be used.

[0099] As will be appreciated by those skilled in the art, although the determination made according to the present invention is preferred, it may not be correct for 100% of the subjects studied. The term generally requires the ability to correctly assess a statistically significant portion of subjects. Those skilled in the art can use various well-known statistical evaluation tools (e.g., determining confidence intervals, determining p-values, Student's t-tests, Mann-Whitney tests, etc.) to effortlessly determine whether a portion is statistically significant. For detailed information, see Dowdy and Wearden, Statistics for Research, John Wiley & Sons, New York 1983. The confidence intervals generally envisioned are at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%. The p-value is typically 0.2, 0.1, 0.05. Therefore, as used herein, when determining whether a subject suffers from invasive PCa, determining (determining / determination) can be directed to the possibility that someone suffers from invasive PCa.

[0100] The terms "cancer" and "cancerous" refer to or describe the physiological condition that is typically characterized by uncontrolled cell growth. Examples of cancer include genitourinary tract cancers, such as PCa. As used herein, the term "prostate cancer (PCa)" refers to all stages and all forms of cancer arising from prostate tissue.

[0101] As used herein, the term "prostate disease" refers to any and all diseases or disorders of the prostate, such as PCa (whether slow growing / indolent or aggressive), prostatitis (including bacterial prostatitis - acute or chronic bacterial infection and non-bacterial prostatitis), inflammation of the prostate (also known as chronic pelvic pain syndrome (CPPS)), and BPH.

[0102] As used herein, "grey zone", "PSA grey zone", "grey area" or "PSA grey zone" refers to a total PSA in the serum of a subject in the range of 2 ng / ml to 10 ng / ml. As described elsewhere herein, the PSA test is a non-deterministic measurement, and a subject with a total serum PSA level in the range of 2 ng / ml to 10 ng / ml may or may not have PCa. The methods of the present invention are particularly suitable for subjects whose serum PSA levels are in this "grey zone". Suitably, the methods of the present invention are performed on samples from subjects whose serum PSA levels are in this "grey zone".

[0103] Methods for diagnosis and staging of PCa are well known in the art. For example, according to the tumor, node, metastasis (TNM) staging system of the American Joint Committee on Cancer (AJCC) AJCC Cancer Staging Manual (7th edition, 2010), the various stages of PCa are defined as follows: Tumor: T1: clinically inapparent tumor that cannot be palpated or cannot be seen by imaging, T1a: histologically incidental tumor in 5% or less of the resected tissue, T1b: histologically incidental tumor in more than 5% of the resected tissue, T1c: tumor identified by needle biopsy; T2: tumor confined to the prostate, T2a: tumor involving half or less of one lobe, T2b: tumor involving more than half of one lobe but not both lobes, T2c: tumor involving both lobes; T3: tumor extending through the prostate capsule, T3a: extracapsular extension (unilateral or bilateral), T3b: tumor invading the seminal vesicle; T4: tumor is fixed or invades adjacent structures other than the seminal vesicle (bladder neck, external sphincter, rectum, levator muscles, or pelvic wall). Lymph nodes: N0: no regional lymph node metastasis; N1: regional lymph node metastasis. Metastasis: M0: no distant metastasis; M1: distant metastasis.

[0104] The Gleason grading system is also commonly used to help assess the prognosis of men with PCa. It is incorporated into the PCa staging strategy, along with other parameters, which predicts prognosis and helps guide therapy. Gleason "scores" or "grades" are given according to the microscopic appearance of PCa. Tumors with low Gleason scores (e.g., Gleason scores ≤ 6) usually grow slowly enough that the tumor may not pose a major threat to the patient's lifetime. Over time, these patients are monitored ("watchful waiting" or "active monitoring"). Cancers with higher Gleason scores are more aggressive and have a poorer prognosis, and these patients are usually treated with surgery (e.g., radical prostatectomy) and in some cases with therapy (e.g., radiation, hormones, ultrasound, chemotherapy, immunotherapy). The Gleason score (or sum) includes the grades of the two most common tumor patterns. These patterns are called Gleason patterns 1-5, with pattern 1 being the best differentiated. Most have a mixture of patterns. To obtain a Gleason score or grade, the main pattern is added to the second most common pattern to obtain a number between 2 and 10. Gleason grades include: G1: well differentiated (mild dysplasia) (Gleason 2-4); G2: moderately differentiated (moderate dysplasia) (Gleason 5-6); G3-4: poorly differentiated / undifferentiated (marked dysplasia) (Gleason 7-10).

[0105] As used herein, "indolent prostate disease" refers to a subject / patient having a Gleason score of ≤6.

[0106] As used herein, "aggressive prostate cancer" or "aggressive PCa" refers to a subject / patient that has a Gleason score of ≥ 7. For example, such a score may be 3+4.

[0107] Methods described herein can be used on samples from patients with prostate disease or with an increased risk of developing PCa. In this context, the phrase "increased risk" indicates that the subject has a higher level of risk (or probability) that they will experience a specific clinical outcome. If there is a family history of PCa, the subject may be at an increased risk of developing the disease. If the subject has a gene mutation that is prone to developing PCa (e.g., BRCA1 and BRCA2 and HPC1, androgen receptor mutations and TMPRSS2:ERG gene fusions), they may be at an increased risk of developing PCa.

[0108] Biomarkers are features that are objectively measured and evaluated as indicators of the biological state of the system (e.g., normal biological processes, pathological processes, or pharmacological responses to therapeutic interventions). Biomarkers can be any type of molecule present in a living organism, such as nucleic acids (DNA, mRNA, miRNA, rRNA, etc.), proteins, polypeptides, peptides, immunologically detectable fragments thereof (cell surface receptors, plasmin, etc.), metabolites or hormones (blood sugar, insulin, estrogen, etc.), molecular features of certain modifications of another molecule (e.g., sugar moieties or phosphoryl residues on proteins, methyl residues on genomic DNA). Suitably, biomarkers are differentially present in samples taken from subjects with a disease or disease state compared to subjects without the disease or disease state. If the mean or median level of the biomarkers in the different groups calculated is statistically significant, the biomarkers are differentially present. Common tests for statistical significance include, among others, t-tests (e.g., Student's t-tests), ANOVA, Kruskal-Wallis, Wilcoxon, Mann-Whitney, receiver operating characteristics (ROC curves), accuracy, and odds ratios. Biomarkers, alone or in combination, provide a measure of the relative risk that a subject belongs to one phenotypic state or another. Therefore, they can be used as markers for disease (diagnosis), drug treatment effects, and drug toxicity.

[0109] Typically, the biomarkers referred to herein are N-linked glycans attached to the PSA protein via the nitrogen atom of asparagine. Glycans are carbohydrate or sugar-based units composed of monosaccharides linked by glycosidic bonds. The PSA glycoforms herein are biomarkers.

[0110] The terms "disease" and "illness" are used interchangeably herein and refer to abnormal conditions, especially abnormal medical conditions, such as illness or injury, in which tissues, organs or individuals / subjects are no longer able to effectively perform their functions. Typically, but not necessarily, a disease is associated with specific symptoms or signs indicating the presence of such a disease. Therefore, the presence of such symptoms or signs may indicate a tissue, organ or individual suffering from a disease. Changes in these symptoms or signs may indicate the progression of the disease. The typical feature of disease progression is an increase or decrease in these symptoms or signs, which may indicate a "deterioration" or "improvement" of the disease. A "deterioration" of a disease is characterized by a decrease in the ability of a tissue, organ or organism to effectively perform its function, while a "recovery" of a disease is typically characterized by an increase in the ability of a tissue, organ or organism to effectively perform its function. Tissues, organs or individuals with a "risk of developing" a disease are in a healthy state, but show the possibility of developing the disease. Typically, the risk of developing a disease is associated with early or weak signs or symptoms of the disease. In this case, the onset of the disease can still be prevented by treatment. Examples of diseases include, but are not limited to, PCa and prostatitis.

[0111] "Glycan" or "carbohydrate" refers to a polymer composed of monosaccharide residues or sugar moieties, which are found attached to proteins, such as in glycoproteins, proteoglycans and lipids. Glycans can be linear or branched. Glycans can be found covalently linked to non-sugar moieties (such as lipids or proteins). Binding to proteins usually occurs via nitrogen (N-linked) or oxygen atoms (O-linked). Covalent conjugates containing glycans are referred to as, for example, glycosylated polypeptides, glycoproteins, glycopeptides, peptidoglycans, proteoglycans, glycolipids and lipopolysaccharides. Glycans also exist in free form (i.e., separated from another part and not associated with it).

[0112] As used herein, the terms "PSA glycoform", "PSA glycoform species", "PSA glycopeptide", "PSA glycan" are used interchangeably and, when in the singular, refer to one specific type of glycan structure attached to the PSA protein or its peptides. When in the plural context, it refers to a variety of PSA glycoforms / glycoform species. The term "glycosylation marker" or "glycan biomarker" may also be used to indicate a specific glycan species associated with PSA, whose levels are altered (enhanced or decreased) in certain disease states (e.g., indolent prostate disease or aggressive PCa) and can therefore be used in the methods of the present invention, including measurement.

[0113] Prostate specific antigen (PSA) has a single site at which N-linked glycosylation occurs, namely at amino acid residue 69 (numbering according to Kabat, EA et al., Sequences of Proteins of Immunological Interest, 1991). Proteases can be used to cleave the PSA protein into smaller peptides, ideally with only one unique peptide having an asparagine at position 69 (so that all different glycoforms are on peptides of the same length), referred to herein as N-containing peptides. 69 Glycopeptide or N 69 Glycopeptides. Cleavage of PSA with trypsin will release N 69 K dipeptide. Cleavage of PSA with Arg-C (clostripain) will release N 69 KSVILLGR peptide (SEQ ID NO: 3). 69 Any glycans attached to the 69 Glycopeptides, such as N 69 K glycopeptide or N 69 KSVILLGR glycopeptide) is present, and thus the level of each PSA-glycan moiety detected according to the method of the present invention can be determined by each N 69 The relative quantification of the levels of K-glycoforms (PSA-glycan species or PSA-glycan moieties) was determined.

[0114] As used herein, the term "N69 glycopeptide" or "glycopeptide comprising N69" refers to any peptide (e.g., 20 amino acids or shorter) derived from PSA (e.g., by protease digestion) that comprises a residue corresponding to N69 of PSA and an N-glycan (e.g., a specific glycoform) attached to N69.

[0115] The glycan / carbohydrate / glycoform species or portions of the present invention will be described with reference to the commonly used nomenclature for describing oligosaccharides (e.g., see Glycobiology 25:1323-1324, 2015 and Glycobiology 29:620-624, 2019; and the legend below Table 1A herein). A review of carbohydrate chemistry using this nomenclature can be found in Hubbard, SC and Ivatt, RJ, Ann. Rev. Biochem. 50:555-583, 1981. Examples of PSA glycoforms that can be used in the present invention are identified in Table 1.

[0116] The term "glycosylation" means the attachment of a sugar moiety (e.g., a polysaccharide) to a protein. Glycosylation is a form of co-translational and post-translational modification. Suitably, a polysaccharide consists of two or more simple sugars linked together via glycosidic bonds. Most glycosylation in mammalian cells is either N-linked or O-linked to proteins. Typically, polysaccharides are bound via the OH group of serine or threonine (O-linked to produce O-glycosylated polypeptides) or via the amide group (NH2) of asparagine (N-linked to produce N-glycosylated polypeptides). The glycosylation of PSA is N-linked.

[0117] The terms "glycosylated polypeptide", "glycoprotein", "glycosylated peptide" and "glycopeptide" are used interchangeably in this application and refer to a protein or polypeptide or peptide having at least two amino acids, at least one of which has a covalently attached glycan or polysaccharide. In the context of a glycosylated peptide of PSA, in one embodiment it is N 69 K glycopeptide.

[0118] The term "glycoform" refers to a protein, polypeptide or peptide that has a specific type and distribution of polysaccharides attached to it, i.e., if two identical peptides / polypeptides contain glycans with the same number, kind and monosaccharide sequence, they will be of the same glycoform; whereas if two identical peptides (with identical amino acid sequence) contain glycans with different numbers, kinds and monosaccharide sequences, they will be different glycoforms. In the context of PSA glycoforms, this is suitably the N-terminal region to which a specific glycan moiety is attached. 69 K glycopeptide. Glycoforms are also glycosylated polypeptides.

[0119] As used herein, the term "mass spectrometry" or "MS" refers to an analytical technique that identifies a compound by its mass. Typically, a sample is analyzed by generating gas-phase ions from the sample, which are then separated and detected according to their mass-to-charge ratio (m / z). MS techniques generally include (1) ionizing a compound to form a charged compound; (2) calculating the mass-to-charge ratio (m / z), and (3) determining the molecular weight of the charged compound. The compound can be ionized and detected by any suitable means. A "mass spectrometer" typically includes an ionizer and an ion detector. Typically, one or more target molecules are ionized and the ions are subsequently introduced into a mass spectrometer instrument where, due to a combination of magnetic and electric fields, the ions follow a spatial path that depends on mass ("m") and charge ("z").

[0120] Methods for generating gas-phase ions from a sample include electrospray ionization (ESI), matrix-assisted laser desorption ionization (MALDI), surface-enhanced laser desorption ionization (SELDI), and chemical ionization. Any type of mass analyzer can separate ions based on their m / z ratio, including quadrupole mass analyzers (Q), time-of-flight (TOF) mass analyzers, magnetic sector mass analyzers, 3D and linear ion traps (IT), Fourier transform ion cyclotron resonance (FT-ICR) analyzers, and combinations thereof (e.g., quadrupole time-of-flight analyzers or Q-TOF analyzers). Prior to ionization, the sample can undergo chromatographic or electrophoretic separation in one or more dimensions, such as liquid or size exclusion chromatography in one or more dimensions.

[0121] As used herein, the term "matrix-assisted laser desorption ionization" or "MALDI" is an ionization technique that uses laser energy to absorb a matrix to produce ions from macromolecules with minimal fragmentation. The MALDI method is a three-step process. First, the sample is mixed with a suitable matrix material and applied to a metal plate. Second, a pulsed laser irradiates the sample, and third, the sample is protonated (H) in a hot plume of ablative gas. + addition) or deprotonation (H + analyte molecules to ionize them. They can then be accelerated into any mass spectrometer used to analyze them

[0122] As used herein, the term "electrospray ionization" or "ESI" refers to a method in which a high voltage is applied to a liquid to produce an aerosol of very small solution droplets in a solvent vapor. This mist of droplets flows through an evaporation chamber. Based on current understanding, as the droplets become smaller, the surface charge density increases until the natural repulsion between like charges causes ions as well as neutral molecules to be released. ESI differs from other ionization methods in that it can produce multiply charged ions, effectively extending the mass range of the analyzer. Heated ESI is similar, but includes a heat source for heating the sample while in the capillary. Mass spectrometry using ESI is called electrospray ionization mass spectrometry (ESI-MS).

[0123] Prostate-specific antigen (PSA) (also known as kallikrein-related peptidase 3, APS, prostate-specific antigen (PSA), hK3, KLK2A1, P-30 antigen, γ-semioplasmic protein, kallikrein-3, semenogelase, spermin NP_001025218.1 (EC 3.4.21.77), NP_001025219.1 (EC 3.4.21.77), NP_001639.1 (EC3.4.21.77)) is a glycoproteinase encoded by the KLK3 gene. KLK3 is a member of the kallikrein-related peptidase family and is secreted by prostate epithelial cells. PSA mRNA is translated into an inactive 261 amino acid preproPSA precursor. PreproPSA has 24 additional residues that constitute the pro-region (signal polypeptide) and the propolypeptide. Release of the propolypeptide produces a mature extracellular form of 237 amino acids that is enzymatically active. PSA is organ-specific and is therefore produced by epithelial cells of BPH tissue, primary PCa tissue, and metastatic PCa tissue.

[0124] PSA is concentrated in prostate tissue, and serum PSA levels are usually low. The destruction of normal prostate structure, such as caused by prostate disease, inflammation or trauma, can release a large amount of PSA into the circulatory system (e.g., blood). PSA measurement is used to detect potential problems of the prostate and track the progress of PCa therapy. However, PSA is not a specific marker for PCa because its level can increase due to other conditions (including BPH and prostatitis), and it is known that PSA levels are also affected by factors such as trauma, drugs, urinary system operations and inflammation. There is a small amount of PSA in the serum of men with healthy prostates, but PSA in subjects with PCa and other prostate diseases usually increases. It has been shown that the PSA level changes between 40% and 45% in the general population are due to genetic factors (Gudmundsson et al. Sci Transl Med. December 15, 2010; 2 (62): 62ra92.doi: 10.1126 / scitranslmed.3001513).

[0125] As used herein, the terms "sample" or "biological fluid sample", "test sample" and variants thereof encompass biological samples obtained from a patient or subject, which may include blood, plasma, serum, urine, prostatic fluid (such as a prostatic secretion sample), semen, saliva or sputum. For the purposes described herein, a sample is or includes a biological fluid (also referred to herein as a body fluid) sample. Suitably, the sample is a urine sample, such as a digital rectal examination (DRE) urine sample. Suitably, the sample is or has been obtained from or derived from a subject. A DRE urine sample is a sample collected immediately after a DRE. For example, this may involve performing a DRE examination in which a certain pressure is applied to the left and right lobes of the prostate before urination, and an initial urine flow of the first 50 mL (approximately) of urine is collected. This urine is referred to as DRE urine.

[0126] As used herein, in the context of a sample, "providing", "obtaining" or "obtaining" can be any way of having a sample by a "direct" or "indirect" means. Directly obtaining a sample means performing a process (e.g., performing a physical method such as extraction) to obtain the sample. Indirectly obtaining a sample means receiving the sample from another party or source (e.g., a third-party laboratory that directly obtains the sample). In certain embodiments, the methods of the present invention are performed on samples obtained indirectly. In certain embodiments, the methods of the present invention include the additional step of obtaining the sample directly from the subject.

[0127] The methods provided herein can include providing a biological fluid sample (eg, a blood sample or a urine sample) from a subject.

[0128] In general, the methods described herein are ex vivo methods performed using a sample that has been obtained from a subject (ie, the sample is provided for use in the method and steps taken to obtain the sample from the subject are not included as part of the method).

[0129] For the avoidance of doubt, the term "ex vivo" has its ordinary meaning in the art and refers to a method performed in or on a sample obtained from a subject in an artificial environment outside the body of the subject from which the sample has been obtained. In a specific embodiment, the subject biological fluid sample has been previously isolated / obtained from the subject, and sample separation does not form part of the method of the present invention. In another embodiment, sample separation may be a step of the method of the present invention.

[0130] As used herein, the term "subject" refers to an animal, more preferably a mammal, such as a human, chimpanzee, rhesus monkey, dog, cow, horse, cat, rat or mouse, provided that they also have a prostate. The subject is preferably a mammal, and most preferably a human. Suitably, the subject is a male, such as a male human.

[0131] Subjects may be referred to herein as patients. The terms "subject," "individual," and "patient" are used interchangeably herein. Subjects may be symptomatic (e.g., subjects exhibit symptoms associated with PCa or prostate disease), or subjects may be asymptomatic (e.g., subjects do not exhibit symptoms associated with PCa or prostate disease).

[0132] As used herein, "watchful waiting" or "active surveillance" refers to a strategy for managing patients with prostate disease. PCa usually grows slowly and may never cause any problems or symptoms. Many treatments and diagnostic procedures for PCa cause side effects. For some men, these side effects can be long-term and can have a significant impact on their lives. Therefore, watchful waiting is a way to monitor PCa that does not cause any symptoms or problems over time and avoids treatment (unless they develop symptoms). Many men who are on watchful waiting never need any treatment for their PCa.

[0133] According to a first aspect of the present invention, there is provided a method, the method comprising:

[0134] (a) determining the level of at least one monoantennary PSA glycoform and the level of at least one biantennary PSA glycoform in a biological fluid sample from a subject;

[0135] (b) calculating an aggressiveness score for the subject based on the levels determined in (a);

[0136] (c) comparing the aggressiveness score of the subject in (b) with a reference value for the aggressiveness score; and

[0137] (d) using the comparison in (c) to help determine whether the subject has an aggressive form of prostate cancer.

[0138] The method can be used for different purposes. For example, to determine or assist in determining whether a subject has an aggressive form of PCa; or to determine or assist in determining whether a subject has an indolent prostate disease.

[0139] Suitably, there is provided a method of aiding in determining whether a subject has an aggressive form of prostate cancer, the method comprising:

[0140] (a) determining the level of at least one monoantennary PSA glycoform and the level of at least one biantennary PSA glycoform in a biological fluid sample from a subject;

[0141] (b) calculating an aggressiveness score for the subject based on the levels determined in (a);

[0142] (c) comparing the aggressiveness score of the subject in (b) with a reference value for the aggressiveness score; and

[0143] (d) using the comparison in (c) to help determine whether the subject has an aggressive form of prostate cancer.

[0144] Suitably, the comparison and / or calculated score in (b) determines whether the subject has an aggressive form of prostate cancer.

[0145] In certain embodiments, the reference aggressiveness score is or has been determined by taking into account the combined levels of determined PSA glycoforms.

[0146] In certain embodiments, the aggressiveness score for a subject is determined by or takes into account the individual levels of PSA glycoforms.

[0147] In specific embodiments, the aggressiveness score for the subject is determined by considering the combined levels of two or more determined PSA glycoforms, wherein at least one PSA glycoform is a monoantennary PSA glycoform and at least one PSA glycoform is a biantennary PSA glycoform.

[0148] In certain embodiments, the aggressiveness score for a subject is determined by considering the combined levels of two or more identified PSA glycoforms (eg, two or more monoantennary or two or more biantennary PSA glycoforms) that share structural features.

[0149] In certain embodiments, the aggressiveness score for a subject may include a ratio of the level of one determined PSA glycoform relative to another (e.g., a ratio of a monoantennary PSA glycoform to a biantennary PSA glycoform, or a ratio of a biantennary PSA glycoform to a monoantennary PSA glycoform), or may be determined by constructing the ratio

[0150] In a variation of the first aspect of the invention, there is provided a method of aiding in determining whether a subject has an aggressive form of prostate cancer, the method comprising:

[0151] (a) determining the level of at least one monoantennary PSA glycoform and the level of at least one biantennary PSA glycoform in a biological fluid sample from a subject;

[0152] (b) comparing the level of each PSA glycoform with a control value or reference value for the PSA glycoform and / or calculating a score for assessing whether the subject has aggressive PCa by taking into account the level of each PSA glycoform; and / or comparing the value of the combined level of each measured PSA glycoform with a control value or reference value for the combined PSA glycoform and / or calculating a score for assessing whether the subject has aggressive PCa by taking into account the combined level of each determined PSA glycoform; and

[0153] (c) using the comparison and / or the calculated score in (b) to assist in determining whether the subject has an aggressive form of prostate cancer.

[0154] In a specific embodiment, the subject is an animal, more preferably a mammal. For example, a human, chimpanzee, rhesus monkey, dog, cow, horse, cat, rat or mouse, provided that they also have a prostate. The subject is preferably a mammal, and most preferably a human. Suitably, the subject is a male, such as a male human.

[0155] In certain embodiments, if the subject is not determined to have an aggressive form of PCa, they are determined to have or to be likely to have indolent prostate disease.

[0156] In particular embodiments, at least one monoantennary PSA glycoform and at least one biantennary PSA glycoform are selected from the monoantennary PSA glycoforms identified as compounds 2, 3, 4 or 5 in Tables 1A and 1B and the biantennary PSA glycoforms identified as compounds 7, 9, 10, 11, 13, 16, 18, 21, 24 and 25 in Tables 1A and 1B.

[0157] In other specific embodiments, at least one monoantennary PSA glycoform and at least one biantennary PSA glycoform are selected from the monoantennary PSA glycoforms identified as compounds 2, 3 and 4 in Tables 1A and 1B and the biantennary PSA glycoforms identified as compounds 7, 9, 18, 11, 13, 24 in Tables 1A and 1B.

[0158] In other specific embodiments, at least one monoantennary PSA glycoform and at least one biantennary PSA glycoform are selected from the monoantennary PSA glycoforms identified as compounds 2, 3, 4 and 5 in Tables 1A and 1B and the biantennary PSA glycoforms identified as compounds 7, 9, 24 and 18 in Tables 1A and 1B.

[0159] In certain embodiments, at least one monoantennary PSA glycoform is selected from the group consisting of: H4N3S 2,6 1(Compound 2); H4N3F1S 2,6 1(Compound 3); H4N3F1S 2,3 1 (compound 4); and H3N4F1S 2,6 1(Compound 5).

[0160] In certain embodiments, at least one biantennary PSA glycoform is selected from the group consisting of: H4N4F1S 2,6 1(Compound 7); H5N4F1S 2,6 1(Compound 9); H5N4F1S 2,3 1(Compound 10); H4N5F1S 2,6 1(Compound 11); H5N4S 2,3 1S 2,6 1(Compound 13); H4N5S 2,3 1S 2,6 1(Compound 16); H4N5F1S 2,3 1S 2,6 1(Compound 18); H4N5S 2,3 1(SO3)1(Compound 21); H4N5F1S 2,6 1(SO3)1 (Compound 24); and H4N5F1S 2,6 1(SO3)1(Compound 25).

[0161] In a specific embodiment, at least one biantennary PSA glycoform is a biantennary PSA glycoform comprising an α2,6-linked sialylation. Such biantennary and α2,6-linked sialylated PSA glycoforms can be selected from the group consisting of compounds 18, 7, 9, 11, 13, 16, 18, 21 and 25 in Tables 1A and 1B.

[0162] In certain embodiments, at least one biantennary PSA glycoform is a biantennary PSA glycoform comprising an α2,6-linked sialylated and fucosylated. Such biantennary α2,6-linked sialylated and fucosylated PSA glycoforms may be selected from the group consisting of: compounds 18, 7, 9, 11, 21 and 25 in Tables 1A and 1B. In embodiments, such biantennary α2,6-linked sialylated and fucosylated PSA glycoforms may be selected from the group consisting of: compounds 18, 7 and 9 in Tables 1A and 1B.

[0163] In a specific embodiment, at least one biantennary PSA glycoform is a biantennary PSA glycoform comprising α2,3 linked sialylation. Such biantennary and α2,3 linked sialylated PSA glycoforms can be selected from the group consisting of: compounds 10, 13, 16, 18, 21, 24, and 25 in Tables 1A and 1B. In a specific embodiment, at least one biantennary PSA glycoform is a biantennary PSA glycoform comprising α2,6 linked sialylation and α2,3 linked sialylation. Such biantennary α2,6 linked sialylation and α2,3 linked sialylated PSA glycoforms can be selected from the group consisting of: compounds 13, 16, and 21 in Tables 1A and 1B.

[0164] In specific embodiments, the methods of the invention can determine whether a subject has aggressive PCa if the level of at least one monoantennary PSA glycoform is reduced and the level of at least one biantennary PSA glycoform is increased in a sample from the subject when compared to an appropriate control or reference level or value.

[0165] It will be understood that different test samples may contain different amounts of PSA, and therefore the absolute levels of any PSA-glycan species detected in a sample will need to be normalized. Normalization is a standard method for diagnostic testing. The levels of measured PSA-glycan species can be normalized based on the amount of PSA in the original sample. Alternatively, normalization can be built into the test assay by spiking the sample to be analyzed with a known amount of a reference analyte or marker. For example, the examples herein determine PSA-glycan levels by reference to a known amount of a specific peptide added / spiked into a sample digested with a protease (e.g., digested with trypsin or Arg-C (clostripain)). Therefore, in a particular embodiment, in order to normalize the levels, the sample analyzed by MS can be spiked with a known amount of a reference PSA peptide derivative (spiked-in peptide). Suitably, the spiked peptide may be a peptide that differs from the native PSA peptide (released during protease digestion) by a single amino acid and is therefore classified as a PSA-peptide derivative, and MS quantification of a known amount of the PSA-peptide derivative together with quantification of the endogenous peptide allows normalization of the level of any and every measured PSA-glycan species in the test / case sample. In one embodiment, the spiked peptide may comprise a sequence as disclosed in SEQ ID NO: 2. In another embodiment, the spiked peptide may be labeled, for example, radioactively labeled. Various methods for normalization are known to those skilled in the art.

[0166] In a specific embodiment of the invention, the detected level of each PSA-glycan species is normalized. In a specific embodiment, the normalized level of one or each PSA-glycan species is determined and used to determine the aggressiveness score.

[0167] If ratios or other equations involving levels of multiple PSA glycoforms are used, normalization may not be necessary.

[0168] In a specific embodiment of the invention, the reference value for the aggressiveness score has been determined from at least one reference population comprising subjects with aggressive PCa and / or subjects without aggressive PCa, such as patients with prostatitis, BPH or indolent PCa.

[0169] In a specific embodiment of the invention, if the level of at least one monoantennary PSA glycoform is decreased and the level of at least one biantennary PSA glycoform is increased compared to a control or reference value, the subject is determined to have an aggressive form of PCa. If not, the subject is determined not to have an aggressive form of PCa or to have indolent prostate disease.

[0170] In a specific embodiment of the invention, an aggressiveness score is calculated for a subject based on the ratio of the levels of each measured PSA glycoform determined from the sample.

[0171] In a specific embodiment of the invention, the method comprises calculating a score for assessing whether the subject has aggressive PCa by taking into account the combined level of each determined PSA glycoform.

[0172] In a specific embodiment of the invention, the method comprises calculating a score for assessing whether a subject has aggressive PCa (aggressive score) by taking into account the individual levels of at least one monoantennary PSA glycoform and at least one biantennary PSA glycoform.

[0173] In a specific embodiment, comparison of individual levels of at least one monoantennary PSA glycoform and at least one biantennary PSA glycoform to appropriate reference levels is used to aid in determining whether a subject has an aggressive form of PCa.

[0174] In a specific embodiment, comparison of the combined level of at least one monoantennary PSA glycoform and at least one biantennary PSA glycoform compared to a reference level for said combined PSA glycoforms is used to aid in determining whether a subject has an aggressive form of PCa.

[0175] In a specific embodiment, the aggressiveness score is used to aid in determining whether a subject has an aggressive form of PCa.

[0176] In a specific embodiment, the score in step (b) comprises or is generated by the ratio of at least one monoantennary PSA glycoform to at least one biantennary PSA glycoform or the ratio of at least one biantennary PSA glycoform to at least one monoantennary PSA glycoform.

[0177] In a specific embodiment, a ratio value comprising a ratio of (i) to (ii) or a ratio of (ii) to (i) is prepared, wherein (i) is the normalized level of at least one monoantennary PSA glycoform in the sample and (ii) is the normalized level of at least one biantennary PSA glycoform in the sample, optionally, the ratio value is used to calculate a risk score for assessing whether a subject has aggressive PCa, and wherein the ratio value or risk score is then compared to a control value or reference value to determine whether the subject has an aggressive form of PCa.

[0178] The method can be applied using measurements from one or more monoantennary species and one or more biantennary species in a test sample.

[0179] In a specific embodiment, the levels of all measured monoantennary species are summed (added), and the levels of all measured biantennary species are summed, and one total value is divided by the other to obtain a ratio or "invasiveness score". It should be understood that if only one monoantennary species or one biantennary species in the category is measured, the level of that species is considered to be the total level. In this way, the method can be adopted using one monoantennary species and two or more biantennary species or one biantennary species and two or more monoantennary species.

[0180] In a particular embodiment of the first aspect of the invention, at least three PSA glycoforms are determined.

[0181] In a particular embodiment of the first aspect of the invention at least 4 PSA-glycoforms are determined.

[0182] In a particular embodiment of the first aspect of the invention at least 5 PSA-glycoforms are determined.

[0183] In a particular embodiment of the first aspect of the invention at least 6 PSA-glycoforms are determined.

[0184] The inventors have found that in subjects with aggressive PCa, the levels of each monoantennary PSA glycoform (e.g., compounds 2, 3, 4, and 5) measured in a biological fluid sample (e.g., in urine) are reduced. However, the levels of most of the biantennary PSA glycoforms tested (including, for example, compounds 7, 9, 18, 24 (see Tables 1A and 1B or Table 6)) are increased in subjects with aggressive PCa.

[0185] In a specific embodiment, the PSA glycoform used or determined in the method of the present invention includes a PSA glycoform selected from any one of the combinations shown in Table 7, having an AUC (1xCV) of at least 66.0, preferably having an AUC (1xCV) of at least 68.0.

[0186] In a specific embodiment, the PSA glycoform used or determined in the methods of the present invention comprises a PSA glycoform selected from the group consisting of:

[0187] (i) H4N3F1S 2,6 1 and H4N4F1S 2,6 1;

[0188] (ii) H4N3F1S 2,6 1 and H5N4F1S 2,6 1;

[0189] (iii) <h2 style=";text-align:left;direction:ltr">H4N3S<h2 style=";text-align:left;direction:ltr"> 2,6 <h2 style=";text-align:left;direction:ltr"> 1 and H4N5S 2,3 1(SO3)1;

[0190] (iv) <h2 style=";text-align:left;direction:ltr">H4N3S<h2 style=";text-align:left;direction:ltr"> 2,6 <h2 style=";text-align:left;direction:ltr"> 1and H5N4F1S2,31S 2,6 1;

[0191] (v) <h2 style=";text-align:left;direction:ltr">H4N3S<h2 style=";text-align:left;direction:ltr"> 2,6 <h2 style=";text-align:left;direction:ltr"> 1 and H4N4F1S 2,6 1;

[0192] (vi) H4N3F1S 2,6 1 and H5N4F1S2,31S 2,6 1;

[0193] (vii) <h2 style=";text-align:left;direction:ltr">H4N3S<h2 style=";text-align:left;direction:ltr"> 2,6 <h2 style=";text-align:left;direction:ltr"> 1 and H4N5F1S 2,3 1S 2,6 1;

[0194] (viii) <h2 style=";text-align:left;direction:ltr">H4N3S<h2 style=";text-align:left;direction:ltr"> 2,6 <h2 style=";text-align:left;direction:ltr"> 1 and H4N5F1S 2,6 1; and

[0195] (ix) H3N4F1S 2,6 1 and H4N5F1S2,31S 2,6 1.

[0196] As can be seen from Table 1B, H4N3S 2,6 1. H4N3F1S 2,6 1. H3N4F1S 2,6 1 (underlined directly above) is the monoantennary compounds 2, 3 and 5.

[0197] In a specific embodiment of the first aspect of the invention, the levels of at least two PSA glycoforms, at least one monoantennary PSA-glycan species and at least one biantennary PSA-glycan species, are determined or measured. In a specific embodiment of the first aspect of the invention, the levels of only two PSA glycoforms, one being a monoantennary PSA-glycan species and the other being a biantennary PSA-glycan species, are determined or measured. In a specific embodiment, the two PSA glycoforms measured are those identified in any of the immediately above groups (i) to (ix) or immediately below groups (a) to (i).

[0198] In other specific embodiments, the PSA glycoform used or determined in the methods of the present invention comprises a PSA glycoform selected from the group consisting of:

[0199] (a)H4N4F1S 2,6 1 and a combination of monoantennary glycoforms;

[0200] (b)H4N3S 2,6 1 and a combination of monoantennary glycoforms;

[0201] (c)H4N3S 2,6 1 and a2.3. Combination of sialylated glycoforms;

[0202] (d)H4N3S 2,6 1 and a2.6. Combination of sialylated glycoforms;

[0203] (e)H5N4F1S 2,3 1S 2,6 1 and a combination of monoantennary glycoforms;

[0204] (f)H5N4F1S 2,3 1 and a combination of monoantennary glycoforms;

[0205] (g) a2.3. A combination of sialylated glycoforms and a combination of monoantennary glycoforms;

[0206] (h)H4N5F1S 2,3 1S 2,6 1 and a combination of monoantennary glycoforms; and

[0207] (i)H4N3F1S 2,3 1 and a combination of monoantennary glycoforms.

[0208] In specific embodiments, in each of (a) to (i) above, the combination of one type of glycan structures (e.g., a combination of monoantennary glycoforms) includes at least two members, such as 2, 3, 4 or more members from the same type of glycan, for example as shown in Tables 1A and 1B.

[0209] In other specific embodiments, in each of (a) to (i) above, the combination of a class of glycan structures (eg, a combination of monoantennary glycoforms) includes all members of the class, as shown in Tables 1A and 1B.

[0210] Suitable monoantennary PSA glycoforms for use in the methods of the invention are selected from compounds 2, 3, 4, and 5, as identified in Tables 1A and 1 B. Suitable biantennary PSA glycoforms for use in the methods of the invention are selected from one or more of compounds 7, 9, 10, 11, 13, 16, 18, 21, 24, and 25, as identified in Tables 1A and 1 B.

[0211] In certain embodiments of the first aspect of the invention, the levels of 3, 4, 5 or more PSA glycoforms are determined or measured.

[0212] In a specific embodiment, the PSA glycoform used or determined in the method of the present invention includes a PSA glycoform selected from any one of the combinations shown in Table 8, having an AUC (1xCV) of at least 70.0, preferably having an AUC (1xCV) of at least 72.0.

[0213] In a specific embodiment, the PSA glycoform used or determined in the method of the present invention includes a PSA glycoform selected from any one of the combinations shown in Table 9, having an AUC (1xCV) of at least 70.0, preferably having an AUC (1xCV) of at least 72.0.

[0214] In a specific embodiment, the PSA glycoform used or determined in the method of the present invention includes a PSA glycoform selected from any one of the combinations shown in Table 10, having an AUC (1xCV) of at least 73.0, preferably having an AUC (1xCV) of at least 72.5.

[0215] In a specific embodiment, the combination of PSA glycoforms used is a combination of monoantennary PSA glycoforms selected from at least two of compounds 2, 3, 4 and 5 and a combination of biantennary PSA glycoforms selected from at least two of compounds 7, 9, 18 and 24.

[0216] In certain embodiments, the combination of PSA glycoforms used is selected from the group consisting of:

[0217] (a) Compounds 2, 3 and 5 (as monoantennary species) and Compounds 24, 7 and 9 (as biantennary species);

[0218] (b) compounds 2 and 3 (as monoantennary species) and compounds 7 and 9 (as biantennary species);

[0219] (c) compounds 3 and 5 (as monoantennary species) and compounds 24, 7, and 9 (as biantennary species);

[0220] (d) compounds 2, 3 and 5 (as monoantennary species) and compounds 7 and 9 (as biantennary species);

[0221] (e) compounds 2 and 3 (as monoantennary species) and compound 7 (as biantennary species); and

[0222] (f) Compounds 3 and 5 (as monoantennary species) and compounds 24 and 9 (as biantennary species).

[0223] In a specific embodiment, when the method employs measurement of the levels of two PSA-glycan species, the PSA-glycan species measured / used consist of one PSA-glycan species whose levels are higher (in the + direction) in samples from subjects with aggressive PCa relative to samples from subjects with indolent prostate disease, and one PSA-glycan species whose levels are lower (in the - direction) in samples from subjects with aggressive PCa relative to samples from subjects with indolent prostate disease. A suitable combination of two PSA-glycan species for use in the methods of the invention is any one of the combinations shown in Table 7.

[0224] In a specific embodiment, when the method employs measurement of three PSA glycoform levels, the PSA-glycoforms measured / used consist of two PSA glycoforms (PSA-glycan species) whose levels increase (+ direction) in samples of subjects with aggressive PCa, and one PSA-glycan species (PSA glycoform) whose levels decrease (- direction) in samples of subjects with aggressive PCa. A suitable combination of three PSA glycoforms for use in the method of the invention is any one of the combinations shown in Table 8.

[0225] In a specific embodiment, when the method employs measurement of four PSA glycoform levels, the PSA-glycoforms measured / used consist of three PSA-glycan species whose levels increase (+ direction) in samples from subjects with aggressive PCa, and one PSA glycoform whose levels decrease (- direction) in samples from subjects with aggressive PCa. A suitable combination of four PSA glycoforms for use in the methods of the invention is any one of the combinations shown in Table 9.

[0226] In certain embodiments of any aspect of the invention, the aggressiveness score is calculated by or comprises: (i) a weighted calculation or (ii) a ratio of PSA glycoform levels.

[0227] In a particular embodiment, a calculation based on or including a ratio of PSA glycoform species levels is performed, wherein the level of at least one PSA glycoform known to be increased in subjects with aggressive PCa and the level of at least one PSA glycoform known to be decreased in subjects with aggressive PCa are used. Suitably, the PSA glycoform known to be decreased in subjects with aggressive PCa is a monoantennary PSA glycoform. Suitably, the PSA glycoform known to be increased in subjects with aggressive PCa is a biantennary PSA glycoform.

[0228] In particular embodiments, the methods of the invention employ a combination of PSA glycoforms of one glycan class and a combination of PSA glycoforms of another glycan class. Suitably, one glycan class comprises monoantennary PSA glycoform species. Suitably, one glycan class comprises biantennary PSA glycoform species or a subset thereof. By a subset thereof, we mean that the biantennary species also has one or more specific types of glycosylation (such as sialylation, fucosylation, etc.).

[0229] In certain embodiments, the aggressiveness score calculation comprises forming a ratio of the total level of the combination of PSA glycoform species from one PSA glycoform class to the total level of the combination of PSA glycoform species from different PSA glycoform classes, or consists of the ratio. In certain embodiments, one of the classes of PSA glycoform species is a monoantennary class of PSA glycoform species. In certain embodiments, one of the classes of PSA glycoform species is a biantennary class of PSA glycoform species.

[0230] In specific embodiments, the aggressiveness score is calculated by the ratio of the total level of the combination of monoantennary PSA glycoform species to the total level of the combination of biantennary PSA glycoform species. Specific examples of combinations are provided in Table 10 below.

[0231] In a specific embodiment, the aggressiveness score is calculated by the ratio of the total level of the combination of mono-PSA glycoform species to the total level of the combination of biantennary PSA glycoform species with fucosylation.

[0232] In a specific embodiment, the aggressiveness score is calculated by the ratio of the total level of the combination of mono-PSA glycoform species to the total level of the combination of biantennary PSA glycoform species with α2,3 sialylation.

[0233] In a specific embodiment, the aggressiveness score is calculated by the ratio of the total level of the combination of mono-PSA glycoform species to the total level of the combination of biantennary PSA glycoform species with α2,6 sialylation.

[0234] The present inventors have found that determining aggressiveness based on the ratio of PSA glycoform species levels is particularly effective and, in fact, results in an improvement in performance in assessing aggressiveness (see Table 10).

[0235] One advantage of calculating the aggressiveness score based on the ratio of PSA glycoform species levels is that no level normalization is required (as normalization would be eliminated by ratio formation).

[0236] The methods of the present invention can be used on any suitable subject. Such subjects may not have had any previous assessment of their prostate. More typically, such subjects may have a digital rectal examination (DRE) and / or a PSA test. The methods of the present invention are particularly suitable for analyzing samples from subjects whose free PSA serum levels are in the gray zone (2ng / mL to 10ng / mL). The methods of the present invention are particularly suitable for analyzing samples from subjects with an enlarged prostate (prostatic hypertrophy).

[0237] Thus, in certain embodiments, the subject suffers from prostate enlargement.

[0238] Suitably, prostate enlargement has been previously determined, for example by DRE or imaging.

[0239] In certain embodiments, the subject has been pre-selected based on having prostate hypertrophy.

[0240] In certain embodiments, the subjects have been pre-selected based on total serum PSA levels.

[0241] In specific embodiments, the subject has a total PSA serum level of 2 ng / mL to 10 ng / mL.

[0242] In a specific embodiment, the subject has been pre-selected based on having a total PSA serum level of 2 ng / mL to 10 ng / mL.

[0243] In certain embodiments, subjects have been preselected based on percent free serum PSA levels.

[0244] In particular embodiments, the subjects have been preselected based on a percentage free serum PSA level of less than or equal to 25%, such as between about 0% and 20%.

[0245] In particular embodiments, the subject has a percent free serum PSA level of less than or equal to 25%, such as between about 0% and 20%.

[0246] The methods of the present invention are based on the measurement of PSA-glycan species levels in a sample from a subject. In a particular embodiment, the sample is a biological fluid sample, such as a body fluid of a subject. In a particular embodiment, the biological fluid sample is selected from the group consisting of: blood, serum, plasma, semen, prostatic fluid and urine.

[0247] In one embodiment, the sample is a urine sample, such as a digital rectal exam (DRE) urine sample.

[0248] In certain embodiments, the PSA protein in the sample is processed to separate the PSA protein from other components in the sample.

[0249] In certain embodiments, the PSA protein in the sample is isolated or purified from the sample. This ensures that any glycan species subsequently detected are species associated with PSA in the sample. In certain embodiments, the PSA protein in the sample is isolated or purified from the sample prior to determining the level of the PSA-glycan species.

[0250] In certain embodiments, the PSA protein in a biological fluid sample of a subject is separated from other components in the sample. In certain embodiments, the PSA protein in a biological fluid sample of a subject is separated from other components in the sample prior to determining the level of the PSA-glycan species.

[0251] As used herein, the terms "separated," "isolated," and "purified" may be used synonymously.

[0252] PSA can be isolated from a sample using various conventional purification methods, such as affinity chromatography. Most suitably, PSA is isolated or purified from a sample by using a PSA binding partner, such as an antibody that can capture the protein, for example, the PSA binding partner / antibody can be bound to a solid surface, such as a microtiter plate or beads, and once PSA is bound to the binding partner, the sample can be washed away, leaving the PSA protein bound to the immobilized PSA binding partner / antibody. The PSA isolated / purified from the sample can then be dissociated from the binding partner.

[0253] In certain embodiments, a biological fluid sample is processed to isolate PSA protein from the sample.

[0254] In a particular embodiment, PSA in a sample is separated from the sample by using a capture binding partner, such as an anti-PSA antibody. Suitably, the capture-binding partner is attached to a solid surface, such as a bead.

[0255] It is necessary to detect and quantify specific glycan species attached to PSA. This can be done using a variety of techniques. Most suitably, detection and quantification are accomplished by mass spectrometry performed after separation of the various analytes, such as by using capillary electrophoresis. To facilitate detection by mass spectrometry, it is convenient to release N-glycans from PSA and analyze the N-glycans separately, or digest PSA (using a suitable protease, such as trypsin) to produce smaller molecules (with intact glycan species) that are more suitable for MS analysis, and analyze the N-glycopeptides.

[0256] Thus, in certain embodiments, PSA in a sample or PSA isolated from a sample is treated to release glycan structures from the PSA.

[0257] PSA is N-glycosylated at the asparagine residue at position 69 (Kabat numbering) of the PSA protein. This position is conveniently located adjacent to the trypsin cleavage site. Therefore, by treating PSA with a suitable protease, such as trypsin or Arg-C (clostripain), the glycan structures attached to PSA can be released as glycopeptide species (different glycoforms).

[0258] In certain embodiments, once the PSA protein is isolated from the sample, it is treated with a protease to generate N 69 Glycopeptide form.

[0259] In certain embodiments, once the PSA protein is isolated from the sample, it is treated with trypsin to generate N 69 K dipeptide glycoform.

[0260] In a specific embodiment, once the PSA protein is isolated from the sample, it is treated with Arg-C (clostripain) to generate N 69 KSVILLGR glycopeptide form. The sequence of the NKSVILLGR peptide is identified herein as SEQ ID NO:3.

[0261] The purified PSA or N produced as described above can be synthesized by treating with a glycosidase. 69 The glycosidase releases glycan species or fragments thereof from the glycopeptide, the glycosidase such as one selected from the group consisting of PNGase F, endoglycosidase F1, endoglycosidase F2, endoglycosidase F3 and endoglycosidase H.

[0262] Thus, in certain embodiments, the isolated / purified PSA or N is treated with a glycosidase. 69 Glycopeptides are derived from PSA protein or N 69 Glycopeptides (e.g., N 69 K or N 69 KSVILLGR glycopeptide) released glycoforms.

[0263] In specific embodiments, the level of each measured PSA glycoform is determined by mass spectrometry such as CE-ESI-MS or LC-ESI-MS( / MS) or MALDI-TOF MS.

[0264] Kammeijer et al. (supra) describe a CE-ESI-MS technique suitable for use in the methods of the present invention.

[0265] In certain embodiments, a specific PSA glycoform is detected as its N 69 K dipeptide glycoform.

[0266] In certain embodiments, a specific PSA glycoform is detected as its N 69 KSVILLGR glycopeptide.

[0267] Methods of the present invention provide valuable information about the prostate disease state of a subject. The ability to more accurately determine whether a subject may suffer from an aggressive form of PCa or an indolent prostate disease provides additional options for further diagnosis or treatment for the attending physician and subject. For example, a subject determined to suffer from an indolent prostate disease can be managed by observation and waiting. A subject determined to suffer from or may suffer from an aggressive PCa can be identified or selected to undergo biopsy testing and / or PCa treatment (such as surgery, radiotherapy, chemotherapy, androgen therapy, etc.).

[0268] Thus, in certain embodiments, the determination made by the methods of the present invention is used to provide treatment recommendations to a subject and / or to determine whether a prostate biopsy is necessary.

[0269] It will be appreciated that the methods may be performed remotely from the subject or their attending physician, and indeed they may be outsourced and the results communicated back.

[0270] In certain embodiments, the results of the methods of the invention (eg, determining whether a subject has an aggressive form of PCa) are provided to a third party, such as the subject or his or her attending physician, laboratory, or health center.

[0271] In a specific embodiment, in the methods of the invention, the aggressiveness score is obtained from an algorithm into which the PSA glycoform level has been input.

[0272] In specific embodiments, the algorithm has been generated by machine learning trained on samples from subjects with aggressive PCa and subjects with indolent PCa and / or BPH and / or healthy subjects.

[0273] The methods of the present invention may involve analyzing a sample from a subject to determine the level of at least one PSA glycoform, and then interpreting the data to determine whether the subject has or may have an aggressive form of PCa. However, the level of one or more PSA glycoforms may have been established, but no inquiry or analysis or data has been performed, and therefore the subject's status cannot be determined. The data for the level of at least one PSA glycoform can be input into a computer, such as via a computer program, for analysis. Suitably, the computer includes software with algorithms and reference values ​​that can deliver a determination of the subject's status.

[0274] According to a second aspect of the present invention, there is provided a method for determining whether a subject suffers from an aggressive form of prostate cancer, the method comprising:

[0275] (i) separating PSA protein from other proteins in a biological fluid sample from a subject;

[0276] (ii) treating the separated PSA protein with a protease;

[0277] (iii) Determine the presence of two or more N 69 The level of each of the glycopeptide forms, where N 69 At least one of the glycopeptide forms is a monoantennary glycoform and N 69 At least one of the glycopeptide forms is a biantennary glycoform;

[0278] (iv) Using each N in (iii) 69The level of glycopeptide forms was used to determine the aggressiveness score for the subject;

[0279] (v) comparing the aggressiveness score of (iv) with a reference value for said aggressiveness score; and

[0280] (vi) determining whether the subject has an aggressive form of PCa based on the comparison in step (v).

[0281] The second aspect of the invention is a subset of the first aspect of the invention, but wherein the sample from the subject is processed to isolate PSA, cleaved with a protease such as trypsin or Arg-C (clostripain), and the N is determined and assessed. 69 Thus, embodiments described in relation to the first aspect of the invention also apply to the second aspect of the invention unless it is clear from the context that they do not apply.

[0282] In certain embodiments, the protease is capable of releasing a protein comprising N 69 In a specific embodiment, the protease is trypsin or Arg-C (clostripain).

[0283] In certain embodiments, the first monoantennary PSA glycoform of step (a) is selected from Compound 2, 3, 4 or 5 (as shown in Tables 1A and 1B).

[0284] In certain embodiments, the first biantennary PSA glycoform of step (b) is selected from compound 7, 9, 10, 11, 13, 16, 18, 21, 24 or 25 (as shown in Tables 1A and 1B).

[0285] The first, second and fourth aspects of the present invention relate to the measurement of the levels of at least two PSA glycoforms. However, as can be seen from Table 2, the levels of three PSA glycoforms (compounds 21, 2 and 9) are able to distinguish aggressive PCa from indolent PCa and BPH with higher specificity (higher AUC) than free PSA when analyzed alone. Therefore, these PSA glycoforms can be used alone in methods to assist in determining whether a subject has aggressive PCa.

[0286] Therefore, according to a third aspect of the present invention, there is provided a method for assisting in determining whether a subject has an aggressive form of prostate cancer, the method comprising:

[0287] (a) determining the level of a PSA glycoform selected from the group consisting of: H4N5F1S in a biological fluid sample from a subject 2,3 1S 2,6 1;H4N3S 2,6 1; and

[0288] H5N4F1S 2,61,

[0289] (b) comparing the value for the PSA glycoform level in (a) with a reference value for the PSA glycoform; or comparing the aggressiveness score taking into account the PSA glycoform level in (a) with a reference value for the aggressiveness score; and

[0290] (c) using the comparison in (b) to help determine whether the subject has an aggressive form of prostate cancer.

[0291] In a particular embodiment, the reference value is a value associated with aggressive PCa. In a particular embodiment, the reference value is a value associated with non-aggressive PCa (such as BPH).

[0292] Embodiments applicable to the first aspect of the invention may be applied to this third aspect of the invention where appropriate.

[0293] In a specific embodiment of the third aspect of the invention, the method relies on H4N5F1S 2,3 1S 2,6 1 (Compound 21) level. In a specific embodiment, H4N5F1S 2,3 1S 2,6 1 (Compound 21) was the only PSA glycoform measured. This PSA glycoform was increased in subjects with aggressive PCa compared to subjects with indolent prostate disease. Thus, in a specific embodiment, if H4N5F1S 2,3 1S 2,6 1 is increased relative to the reference value, the subject is determined to have an aggressive form of PCa. 2,3 1S 2,6 1 relative to the reference value, the subject is determined not to have an aggressive form of PCa and / or is determined to have indolent prostate disease.

[0294] In a particular embodiment of the third aspect of the invention, the method relies on H4N3S 2,6 1 (Compound 2) level. In a specific embodiment, H4N3S 2,6 1 (Compound 2) was the only PSA glycoform measured. Levels of this PSA glycoform were reduced in subjects with aggressive PCa compared to subjects with indolent prostate disease.

[0295] Thus, in certain embodiments, if H4N3S 2,6 1 is decreased relative to the reference value, the subject is determined to have an aggressive form of PCa. 2,61 relative to the reference value, the subject is determined not to have an aggressive form of PCa and / or is determined to have indolent prostate disease.

[0296] In a particular embodiment of the third aspect of the invention, the method relies on H5N4F1S 2,6 1 (Compound 9) level. In a specific embodiment, H5N4F1S 2,6 1 (Compound 9) was the only PSA glycoform measured. The levels of this PSA glycoform were increased in subjects with aggressive PCa compared to subjects with indolent prostate disease.

[0297] Thus, in a particular embodiment, if H5N4F1S 2,6 If the level of 1 is increased relative to the reference value, the subject is determined to have an aggressive form of PCa.

[0298] In another embodiment, if H5N4F1S 2,6 1 relative to the reference value, the subject is determined not to have an aggressive form of PCa and / or is determined to have indolent prostate disease.

[0299] In a particular embodiment of the invention, the detected level of each PSA-glycan is normalized. In a particular embodiment, the normalized level of one or each PSA-glycan is determined and / or compared to a control or reference value.

[0300] In a specific embodiment of the invention, the reference value has been determined from at least one reference population comprising subjects with aggressive PCa and subjects without aggressive PCa, such as patients with prostatitis, BPH or indolent PCa.

[0301] In a specific embodiment of the invention, the method comprises calculating a score for assessing whether a subject has aggressive PCa by taking into account the individual level of at least one PSA glycoform.

[0302] In a specific embodiment, a score calculated by taking into account the level of an individual's PSA glycoforms is used to help determine whether a subject has an aggressive form of PCa.

[0303] In certain embodiments, the subject suffers from prostate enlargement. Suitably, the prostate enlargement has been previously determined, for example, by DRE or imaging.

[0304] In certain embodiments, the subjects have been pre-selected based on total serum PSA levels.

[0305] In certain embodiments, the subject has a total PSA serum level of about 2 ng / mL to 10 ng / mL.

[0306] In certain embodiments, the subject has been preselected based on having a total PSA serum level of about 2 ng / mL to 10 ng / mL.

[0307] In certain embodiments, subjects have been preselected based on percent free serum PSA levels.

[0308] In particular embodiments, the subjects have been preselected based on a percentage free serum PSA level of less than or equal to 25%, such as between about 0% and 20%.

[0309] In particular embodiments, the subject has a percent free serum PSA level of less than or equal to 25%, such as between about 0% and 20%.

[0310] In certain embodiments, the sample is any body fluid containing PSA. In certain embodiments, the sample is a biological fluid sample. In certain embodiments, the biological fluid sample is a body fluid. In certain embodiments, the sample is selected from the group consisting of: blood, serum, plasma, semen, prostatic fluid, and urine.

[0311] In one embodiment, the sample is a urine sample, such as a digital rectal exam (DRE) urine sample.

[0312] In certain embodiments, the PSA protein in the sample is isolated or purified from the sample. This ensures that any glycan species subsequently detected are species associated with the PSA in the sample.

[0313] In certain embodiments, PSA protein in a biological fluid sample from a subject is separated from other components in the sample.

[0314] PSA can be isolated from a sample using various conventional purification methods, such as affinity chromatography. Most suitably, PSA is isolated or purified from a sample by using a PSA binding partner, such as an antibody that can capture the protein, for example, the PSA binding partner / antibody can be bound to a solid surface, such as a microtiter plate or beads, and once PSA is bound to the binding partner, the sample can be washed away, leaving the PSA protein bound to the immobilized PSA binding partner / antibody. The PSA isolated / purified from the sample can then be dissociated from the binding partner.

[0315] In certain embodiments, a biological fluid sample is processed to isolate PSA protein from the sample.

[0316] In a particular embodiment, PSA in a sample is separated from the sample by using a capture binding partner, such as an anti-PSA antibody. Suitably, the capture-binding partner is attached to a solid surface, such as a bead.

[0317] It is necessary to detect and quantify specific glycans attached to PSA. This can be done using a variety of techniques.

[0318] Most suitably, detection and quantification are accomplished by mass spectrometry followed by means of separation of the various analytes, such as by using capillary electrophoresis.

[0319] To facilitate mass spectrometry detection, it is convenient to release glycans from PSA or to treat PSA-glycans to produce smaller molecules (with intact glycan species) that are more suitable for MS analysis.

[0320] Thus, in certain embodiments, PSA in a sample or PSA isolated from a sample is treated to release glycan structures from the PSA.

[0321] In certain embodiments, once the PSA protein is isolated from the sample, it is treated with trypsin to generate N 69 K dipeptide glycopeptide (glycoform).

[0322] In a specific embodiment, once the PSA protein is isolated from the sample, it is treated with Arg-C (clostripain) to generate a protein comprising N 69 of glycopeptides.

[0323] In certain embodiments, the isolated / purified PSA or glycopeptide (e.g., comprising N 69 The glycopeptide forms) are incubated with a glycosidase to release glycoforms from the PSA protein or glycopeptide.

[0324] In specific embodiments, the level of each measured PSA glycoform is determined by mass spectrometry such as CE-ESI-MS or LC-ESI-MS( / MS) or MALDI-TOF MS.

[0325] In certain embodiments, a specific PSA glycoform is detected as its N 69 K dipeptide glycoform or its N 69 KSVILLGR glycopeptide.

[0326] Methods of the present invention provide valuable information about the prostate disease state of a subject. The ability to more accurately determine whether a subject may suffer from an aggressive form of PCa or an indolent prostate disease provides additional options for further diagnosis or treatment for the attending physician and subject. For example, a subject determined to suffer from an indolent prostate disease can be managed by observation and waiting. A subject determined to suffer from or may suffer from an aggressive PCa can be identified or selected to undergo biopsy testing and / or PCa treatment (such as surgery, radiotherapy, chemotherapy, androgen therapy, etc.).

[0327] Thus, in certain embodiments, the determination made by the methods of the present invention is used to provide treatment recommendations to a subject and / or to determine whether a prostate biopsy is necessary.

[0328] In certain embodiments, in the methods of the invention, an algorithm is applied to the PSA glycoform levels to determine whether a subject has an aggressive form of PCa.

[0329] In specific embodiments, the algorithm has been generated by machine learning trained on samples from subjects with aggressive PCa and subjects with indolent PCa and / or BPH and / or healthy subjects.

[0330] The methods of the present invention may involve analyzing a sample from a subject to determine the level of at least one PSA glycoform, and then interpreting the data to determine whether the subject has or may have an aggressive form of PCa. However, the level of one or more PSA glycoforms may have been established, but no inquiry or analysis or data has been performed, and therefore the subject's status cannot be determined. The data for the level of at least one PSA glycoform may be input into a computer for analysis. Suitably, the computer includes software with algorithms and reference values ​​that can deliver a determination of the subject's status.

[0331] Computer-implemented methods

[0332] According to a fourth aspect of the present invention, there is provided a computer-implemented method for assisting in determining whether a subject has an aggressive form of prostate cancer, the method comprising the steps of:

[0333] (a) receiving a value for the level of a first monoantennary PSA glycoform in a biological fluid sample of a subject;

[0334] (b) receiving a value for the level of a first biantennary PSA glycoform in a biological fluid sample of the subject;

[0335] (c) calculating an aggressiveness score for the subject based on the levels received in (a) and (b);

[0336] (d) comparing the aggressiveness score of the subject in (c) with a reference value for the aggressiveness score; and

[0337] (e) using the comparison in (d) to help determine whether the subject has an aggressive form of prostate cancer.

[0338] In certain embodiments, the first monoantennary PSA glycoform of step (a) is selected from Compound 2, 3, 4 or 5 (as shown in Tables 1A and 1B).

[0339] In certain embodiments, the first biantennary PSA glycoform of step (b) is selected from compound 7, 9, 10, 11, 13, 16, 18, 21, 24 or 25 (as shown in Tables 1A and 1B).

[0340] In a specific embodiment, the PSA glycoform used or determined in the fourth aspect of the invention comprises a PSA glycoform selected from any one of the combinations shown in Table 8, having an AUC (1xCV) of at least 70.0, preferably having an AUC (1xCV) of at least 72.0.

[0341] In a specific embodiment, the PSA glycoform used or determined in the fourth aspect comprises a PSA glycoform selected from any one of the combinations shown in Table 9, having an AUC (1xCV) of at least 70.0, preferably having an AUC (1xCV) of at least 72.0.

[0342] In a specific embodiment, the PSA glycoform used or determined in this aspect of the invention comprises a PSA glycoform selected from any one of the combinations shown in Table 10 having an AUC (1xCV) of at least 73.0, preferably having an AUC (1xCV) of at least 72.5.

[0343] In a specific embodiment, the combination of PSA glycoforms used is a combination of monoantennary PSA glycoforms selected from at least two of compounds 2, 3, 4 and 5 and a combination of biantennary PSA glycoforms selected from at least two of compounds 7, 9, 18 and 24.

[0344] In certain embodiments, the combination of PSA glycoforms used is selected from the group consisting of:

[0345] (a) Compounds 2, 3 and 5 (as monoantennary species) and compounds 24, 7 and 9 (as biantennary species).

[0346] (b) Compounds 2 and 3 (as monoantennary species) and compounds 7 and 9 (as biantennary species).

[0347] (c) Compounds 3 and 5 (as monoantennary species) and compounds 24, 7 and 9 (as biantennary species).

[0348] (d) Compounds 2, 3 and 5 (as monoantennary species) and compounds 7 and 9 (as biantennary species).

[0349] (e) Compounds 2 and 3 (as monoantennary species) and compound 7 (as biantennary species).

[0350] (f) Compounds 3 and 5 (as monoantennary species) and compounds 24 and 9 (as biantennary species).

[0351] Embodiments applicable to the first aspect of the invention may be applied to this fourth aspect of the invention where appropriate.

[0352] According to a fifth aspect of the present invention, there is provided a computer-implemented method for assisting in determining whether a subject has an aggressive form of prostate PCa, the method comprising the following steps:

[0353] (a) receiving a value in a biological fluid sample of a subject for the level of a PSA glycoform selected from the group consisting of: H4N5F1S 2,3 1S 2,6 1;H4N3S 2,6 1; and

[0354] H5N4F1S 2,6 1;

[0355] (b) comparing the value for the PSA glycoform level received in (a) with a reference value for the PSA glycoform; or comparing the aggressiveness score taking into account the PSA glycoform level received in (a) with a reference value for the aggressiveness score; and

[0356] (c) using the comparison in (b) to help determine whether the subject has an aggressive form of prostate cancer.

[0357] The value received in (a) may be obtained from the PSA glycoform determined in the third aspect of the invention.

[0358] According to a variation of this fifth aspect of the invention, there is provided a computer-implemented method of assisting in determining whether a subject has an aggressive form of prostate cancer, the method comprising the steps of:

[0359] (a) receiving a value in a biological fluid sample of a subject for the level of a PSA glycoform selected from the group consisting of: H4N5F1S 2,3 1S 2,6 1;H4N3S 2,6 1; and

[0360] H5N4F1S 2,6 1;

[0361] (b) calculating an aggressiveness score for the subject by taking into account the values ​​accepted in (a);

[0362] (c) comparing the aggressiveness score in (b) to a reference aggressiveness score; and

[0363] (d) using the comparison in (c) to help determine whether the subject has an aggressive form of prostate cancer.

[0364] Embodiments applicable to the third aspect of the invention may be applied to this fifth aspect of the invention where appropriate.

[0365] As used herein, the term "computer-implemented" means that the method is performed in an automated manner on a data processing unit, which is typically included in a computer or similar data processing device. The data processing unit should receive values ​​for biomarker levels (i.e., the level of each PSA glycoform). Such values ​​can be amounts, relative amounts, or any other calculated values ​​reflecting amounts as described in detail elsewhere herein. Therefore, it should be understood that the above method does not require determining the amount of a biomarker, but uses values ​​of amounts that have been predetermined.

[0366] In principle, the present invention also envisages a computer program, a computer program product or a computer-readable storage medium having said computer program tangibly embedded therein, wherein the computer program comprises instructions for performing the above-described method of the present invention when the instructions are run on a data processing device or a computer.

[0367] Specifically, the present disclosure further includes:

[0368] - a computer or a computer network comprising at least one processor, wherein the processor is adapted to perform a method according to one of the aspects described in this specification,

[0369] - a computer loadable data structure, which is suitable for carrying out a method according to one of the aspects described in this specification when the data structure is being executed on a computer,

[0370] - a computer script, wherein the computer program is adapted to carry out the method according to one of the aspects described in the present description when the program is being executed on a computer,

[0371] - a computer program comprising program means for carrying out a method according to one of the aspects described in the present description when the computer program is being executed on a computer or on a computer network,

[0372] - a computer program comprising program means according to the preceding embodiment, wherein the program means is stored on a computer-readable storage medium,

[0373] a storage medium, on which a data structure is stored and on which the data structure is suitable for carrying out a method according to one of the aspects described in the present description after having been loaded into a main storage device and / or a working storage device of a computer or a computer network,

[0374] - a computer program product having program code means, wherein the program code means can be stored or are stored on a storage medium for carrying out the method according to one of the aspects described in the present description when the program code means are executed on a computer or on a computer network,

[0375] - a data stream signal, usually encrypted, comprising data of the parameters defined elsewhere herein,

[0376] as well as

[0377] - A data stream signal, usually encrypted, comprising the assessment provided by the method of the invention.

[0378] The methods of the first, second, third, fourth and fifth aspects of the invention can be used to determine or assist in determining whether a subject has an aggressive form of PCa or to determine or assist in determining whether a subject does not have an aggressive form of PCa, such as indolent prostate disease. Suitably, the methods of the first, second, third, fourth or fifth aspects of the invention can be used to determine or assist in determining whether a subject has an indolent disease, such as BPH.

[0379] "Assisted determination" means that other factors may or may not be used in addition to making the determination, so the "assisted" measure is only part of the determination. As used herein, if the result can be determined directly, such as directly from the aggressiveness score, then this can be considered an assisted determination.

[0380] Parts Kit

[0381] According to the sixth aspect of the present invention, a kit for use in the method of the present invention (including any one of the first, second, third, fourth or fifth aspects of the present invention) (or the use of the kit in the method of the present invention) is provided, the kit comprising a scoring system having a PSA glycoform threshold or ratio indicative of aggressive PCa.

[0382] Optionally, the kit also includes instructions for use.

[0383] Optionally, the kit further comprises a PSA binding partner, such as an antibody, in particular a monoclonal antibody, optionally wherein the PSA binding partner is immobilized on a solid surface such as beads.

[0384] Such PSA binding partners can be used to isolate or purify PSA protein. In an embodiment, the kit can include a protease, such as trypsin or Arg C. Trypsin or Arg-C (clostripain) can be used to generate PSA glycopeptides that can be measured via mass spectrometry. In an embodiment, the kit can be a kit for mass spectrometry detection of PSA glycoforms.

[0385] Other aspects and embodiments of the invention

[0386] According to a seventh aspect of the present invention, there is provided a method for determining whether a patient suffers from aggressive prostate cancer or indolent prostate disease, the method comprising:

[0387] (a) determining the level of one or more PSA glycoforms in a urine sample from a patient;

[0388] (b) Calculate the aggressiveness score for the subject by taking into account the levels in (a)

[0389] (c) comparing the aggressiveness score of (b) with a reference value of the aggressiveness score; and

[0390] (d) determining whether the patient has aggressive prostate cancer or indolent prostate disease based on the comparison in step (b).

[0391] In particular embodiments, one or more PSA glycoforms are selected from one or more of the following compounds: 2, 3, 4, 5, 7, 9, 10, 11, 13, 16, 18, 21, 24 and 25, as identified in Tables 1A and 1B. Most suitably, the PSA glycoform is selected from: H4N5F1S 2,3 1S 2,6 1;H4N3S 2,6 1; and H5N4F1S 2,6 1. The embodiments applicable to the third aspect of the present invention may be applied to this seventh aspect of the present invention where appropriate.

[0392] According to an eighth aspect of the present invention, there is provided a method for distinguishing whether a subject is likely to suffer from aggressive prostate cancer or indolent prostate disease, the method comprising the following steps:

[0393] (a) determining or receiving the level of (i) one or more monoantennary PSA glycoforms and (ii) one or more biantennary PSA glycoforms in a biological fluid sample of a subject;

[0394] (b) Calculation of the invasiveness score using the levels detected in (a);

[0395] (c) comparing the invasiveness score determined in step (b) with a reference value of the invasiveness score; and

[0396] (d) determining whether the subject has aggressive prostate cancer or indolent prostate disease based on the comparison in step (c).

[0397] In certain embodiments, the level in step (a) is determined from a biological fluid sample from the subject.

[0398] In particular embodiments, the one or more PSA glycoforms are selected from one or more of the following compounds: 2, 3, 4, 5, 7, 9, 10, 11, 13, 16, 18, 21, 24, and 25, as identified in Tables 1A and 1B.

[0399] In a specific embodiment, the PSA glycoform used or determined in the seventh or eighth aspect of the invention comprises a PSA glycoform selected from any one of the combinations shown in Table 8, having an AUC (1xCV) of at least 70.0, preferably having an AUC (1xCV) of at least 72.0.

[0400] In a specific embodiment, the PSA glycoform used or determined in the seventh or eighth aspect of the invention comprises a PSA glycoform selected from any one of the combinations shown in Table 9 having an AUC (1xCV) of at least 70.0, preferably having an AUC (1xCV) of at least 72.0.

[0401] In a specific embodiment, the PSA glycoform used or determined in the seventh or eighth aspect of the invention comprises a PSA glycoform selected from any one of the combinations shown in Table 10 having an AUC (1xCV) of at least 73.0, preferably having an AUC (1xCV) of at least 72.5.

[0402] In a specific embodiment, the combination of PSA glycoforms used is a combination of monoantennary PSA glycoforms selected from at least two of compounds 2, 3, 4 and 5 and a combination of biantennary PSA glycoforms selected from at least two of compounds 7, 9, 18 and 24.

[0403] In certain embodiments, the combination of PSA glycoforms used is selected from the group consisting of:

[0404] (a) Compounds 2, 3 and 5 (as monoantennary species) and compounds 24, 7 and 9 (as biantennary species).

[0405] (b) Compounds 2 and 3 (as monoantennary species) and compounds 7 and 9 (as biantennary species).

[0406] (c) Compounds 3 and 5 (as monoantennary species) and compounds 24, 7 and 9 (as biantennary species).

[0407] (d) Compounds 2, 3 and 5 (as monoantennary species) and compounds 7 and 9 (as biantennary species).

[0408] (e) Compounds 2 and 3 (as monoantennary species) and compound 7 (as biantennary species).

[0409] (f) Compounds 3 and 5 (as monoantennary species) and compounds 24 and 9 (as biantennary species).

[0410] Embodiments applicable to the first aspect of the invention may be applied to this eighth aspect of the invention where appropriate.

[0411] Table 1A - List of PSA-glycoforms, direction of expression changes in aggressive PCa subjects* and AUC values ​​for single markers.

[0412]

[0413]

[0414]

[0415] abbreviation:

[0416] H: Hex: Hexose, examples are mannose (Man) or galactose (Gal)

[0417] N: HexNAc: N-acetylhexosamine, exemplified by N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc)

[0418] F:Fuc:fucose;deoxyhexose

[0419] S:Neu5Ac:N-acetylneuraminic acid, sialic acid

[0420] S 2,6 :Neu5Ac a2-6:α2,6 linked sialic acid

[0421] S 2,3 :Neu5Ac a2-3:α2,3 linked sialic acid

[0422] (SO3): Sulfate

[0423] * Expression changes reflect the directional change in PSA-glycan expression levels alone (univariate analysis) in subjects with aggressive PCa relative to subjects with indolent prostate disease (indolent PCa or benign hyperplasia), no change = nc; + = up; - = down, ns = not selected.

[0424] Table 1B - Individual PSA-glycan species, the class or category to which they belong and N 69 Mass-to-charge (m / z) ratio of K dipeptide glycoforms

[0425]

[0426] The present invention also provides the following embodiments:

[0427] 1. A method for assisting in determining whether a subject has an aggressive form of prostate cancer, the method comprising:

[0428] (a) determining the level of at least one monoantennary PSA glycoform and the level of at least one biantennary PSA glycoform in a biological fluid sample from a subject;

[0429] (b) calculating an aggressiveness score for the subject based on the levels determined in (a);

[0430] (c) comparing the aggressiveness score of the subject in (b) with a reference value for the aggressiveness score; and

[0431] (d) using the comparison in (c) to help determine whether the subject has an aggressive form of prostate cancer.

[0432] 2. A method for determining whether a subject has an aggressive form of prostate cancer, the method comprising:

[0433] (i) separating PSA protein from other proteins in a biological fluid sample from a subject;

[0434] (ii) treating the separated PSA protein with a protease;

[0435] (iii) Determine the presence of two or more N 69 The level of each of the glycopeptide forms, where N 69 At least one of the glycopeptide forms is a monoantennary glycoform and N 69 At least one of the glycopeptide forms is a biantennary glycoform;

[0436] (iv) Using each N in (iii) 69 The level of glycopeptide forms was used to determine the aggressiveness score for the subject;

[0437] (v) comparing the aggressiveness score of (iv) with a reference value for said aggressiveness score; and

[0438] (vi) determining whether the subject has an aggressive form of PCa based on the comparison in step (v).

[0439] 3. The method of embodiment 2, wherein the protease is selected from the group consisting of trypsin and Arg-C (clostripain).

[0440] 4. The method of embodiment 1, 2 or 3, wherein if the subject is determined not to have an aggressive form of PCa, then they are determined to have indolent prostate disease.

[0441] 5. The method of any one of embodiments 1 to 4, wherein the at least one monoantennary PSA glycoform is selected from the group consisting of: H4N3S 2,6 1;H4N3F1S 2,6 1;H4N3F1S 2,3 1; and H3N4F1S 2,6 1.

[0442] 6. The method of any one of embodiments 1 to 5, wherein the at least one biantennary PSA glycoform is selected from the group consisting of: H4N4F1S 2,6 1;H5N4F1S 2,6 1;H5N4F1S 2,3 1;H4N5F1S 2,6 1; H5N4S 2,3 1S 2,6 1;H4N5S 2,3 1S 2,6 1;H4N5F1S 2,3 1S 2,6 1;H4N5S 2,3 1(SO3)1; and H4N5F1S 2,6 1(SO3)1.

[0443] 7. The method of any preceding embodiment, wherein the levels of 3, 4, 5 or more PSA glycoforms are determined.

[0444] 8. The method of any preceding embodiment, wherein the level of each PSA glycoform determined is normalized.

[0445] 9. A method according to any of the preceding embodiments, wherein the aggressiveness score comprises or consists of: the ratio of the level of the at least one biantennary PSA glycoform from a subject sample to the level of the at least one monoantennary PSA glycoform, or the ratio of the level of the at least one monoantennary PSA glycoform from a subject sample to the level of the at least one biantennary PSA glycoform.

[0446] 10. A method according to any one of the preceding embodiments, comprising a first value corresponding to the level of the at least one monoantennary PSA glycoform and a second value corresponding to the level of the at least one biantennary PSA glycoform, and the reference value for the aggressiveness score comprises a reference value for the first value and a reference value for the second value, and wherein if the level of the at least one monoantennary PSA glycoform is decreased compared to the reference value for the first value, and the level of the at least one biantennary PSA glycoform is increased compared to the reference value for the second value, the subject is determined to have an aggressive form of PCa.

[0447] 11. The method according to any one of the preceding embodiments, wherein the PSA glycoform used or determined in the method of the present invention comprises a PSA glycoform selected from the group consisting of:

[0448] (i)H4N3F1S 2,6 1 and H4N4F1S 2,6 1;

[0449] (ii)H4N3F1S 2,6 1 and H5N4F1S 2,6 1;

[0450] (iii)H4N3S 2,6 1 and H4N5S 2,3 1(SO3)1;

[0451] (iv)H4N3S 2,6 1 and H5N4F1S2,31S 2,6 1;

[0452] (v)H4N3S 2,6 1 and H4N4F1S 2,6 1;

[0453] (vi)H4N3F1S 2,6 1 and H5N4F1S 2,3 1S 2,6 1;

[0454] (vii) H4N3S2,61 and H4N5F1S 2,3 1S 2,6 1;

[0455] (viii)H4N3S 2,6 1 and H4N5F1S 2,6 1;

[0456] (ix)H3N4F1S 2,6 1 and H4N5F1S2,31S 2,6 1.

[0457] 12. The method of any one of embodiments 1 to 10, wherein the PSA glycoform used or determined in the method of the present invention comprises a PSA glycoform selected from the group consisting of:

[0458] a.H4N4F1S 2,6 1 and a combination of monoantennary glycoforms;

[0459] b.H4N3S 2,6 1 and a combination of monoantennary glycoforms;

[0460] c.H4N3S 2,6 1 and a2.3. Combination of sialylated glycoforms;

[0461] d.H4N3S 2,6 1 and a2.6. Combination of sialylated glycoforms;

[0462] e.H5N4F1S 2,3 1S 2,6 1 and a combination of monoantennary glycoforms;

[0463] f.H5N4F1S 2,3 1 and a combination of monoantennary glycoforms;

[0464] g.a2.3. Combinations of sialylated glycoforms and monoantennary glycoforms;

[0465] h.H4N5F1S 2,3 1S 2,6 1 and a combination of monoantennary glycoforms; and

[0466] i.H4N3F1S 2,3 1 and a combination of monoantennary glycoforms.

[0467] 13. A method for aiding in determining whether a subject has an aggressive form of prostate cancer, the method comprising:

[0468] (a) determining the level of a PSA glycoform selected from the group consisting of: H4N5F1S in a biological fluid sample from a subject 2,3 1S 2,6 1;H4N3S 2,6 1; and H5N4F1S 2,6 1,

[0469] (b) comparing the value for the PSA glycoform level in (a) with a reference value for the PSA glycoform; or comparing the aggressiveness score taking into account the PSA glycoform level in (a) with a reference value for the aggressiveness score; and

[0470] (c) using the comparison in (b) to help determine whether the subject has an aggressive form of prostate cancer.

[0471] 14. The method of any one of the preceding embodiments, wherein the subject is a mammal, such as a male human.

[0472] 15. The method of any preceding embodiment, wherein the biological fluid sample is selected from the group consisting of: blood, serum, plasma, semen, prostatic fluid, and urine.

[0473] 16. The method of embodiment 15, wherein the sample is a urine sample, optionally a digital rectal examination (DRE) urine sample.

[0474] 17. The method of any of the preceding embodiments, wherein the subject is preselected based on having prostate hypertrophy.

[0475] 18. The method according to any one of the preceding embodiments, wherein the subject is preselected based on the level of total serum PSA.

[0476] 19. The method of embodiment 18, wherein the level of total serum PSA in the subject is between about 2 ng / ml to 10 ng / ml.

[0477] 20. The method of any preceding embodiment, wherein the PSA protein in a biological fluid sample of the subject is isolated from the sample.

[0478] 21. The method of embodiment 20, wherein PSA is separated from the sample by using a capture binding partner such as an anti-PSA antibody.

[0479] 22. The method of embodiment 20 or 21, wherein the isolated PSA protein is treated with a protease such as trypsin or Arg-C (clostripain) to produce a protein comprising N 69 of glycopeptides.

[0480] 23. The method of any one of embodiments 20 to 22, wherein the isolated PSA or the N-containing 69 The glycopeptides are derived from the PSA protein or N 69 Release of glycoforms from K dipeptide.

[0481] 24. The method according to any one of the preceding embodiments, wherein the

[0482] Mass spectrometry by ESI-MS( / MS) or MALDI-TOF-MS determines the level of each measured PSA glycoform.

[0483] 25. The method of any preceding embodiment, wherein the determination is used to provide treatment recommendations to the patient and / or to determine whether a prostate biopsy is required.

[0484] 26. A method according to any one of embodiments 1 to 12 and 14 to 25, wherein the reference value of the aggressiveness score has been determined from samples of at least one reference population, the reference population comprising: subjects with aggressive PCa; and subjects who do not have aggressive PCa, such as patients with prostatitis, BPH or indolent PCa; optionally wherein the disease state is known.

[0485] 27. The method of any one of claims 13 to 25, wherein the reference value for the PSA glycoform has been determined from samples of at least one reference population, the reference population comprising: subjects with aggressive PCa; and subjects without aggressive PCa, such as patients with prostatitis, BPH or indolent PCa; optionally wherein the disease state is known.

[0486] 28. A kit for use in the method according to any one of embodiments 1 to 27, the kit comprising a scoring system having reference values ​​or ratios of PSA glycoforms indicative of aggressive PCa, and optionally instructions for use.

[0487] 29. The kit of embodiment 28, further comprising a PSA binding partner, such as a monoclonal antibody, optionally wherein the PSA binding partner is immobilized to a solid surface, such as beads.

[0488] 30. Use of a kit in a method according to any one of embodiments 1 to 27, the kit comprising a scoring system having reference values ​​or ratios of PSA glycoforms indicative of aggressive PCa, and optionally instructions for use.

[0489] 31. The use according to embodiment 30, further comprising a PSA binding partner, such as a monoclonal antibody, optionally wherein the PSA binding partner is immobilized on a solid surface such as beads.

[0490] 32. A computer-implemented method for assisting in determining whether a subject has an aggressive form of prostate cancer, the computer-implemented method comprising the steps of:

[0491] (a) receiving a value for the level of a first monoantennary PSA glycoform in a biological fluid sample of a subject;

[0492] (b) receiving a value for the level of a first biantennary PSA glycoform in a biological fluid sample of the subject;

[0493] (c) calculating an aggressiveness score for the subject based on the levels received in (a) and (b);

[0494] (d) comparing the aggressiveness score of the subject in (c) with a reference value for the aggressiveness score; and

[0495] (e) using the comparison in (d) to help determine whether the subject has an aggressive form of prostate cancer.

[0496] 33. A computer-implemented method for assisting in determining whether a subject has an aggressive form of prostate cancer, the computer-implemented method comprising the steps of:

[0497] (a) receiving a value in a biological fluid sample of a subject for the level of a PSA glycoform selected from the group consisting of: H4N5F1S 2,3 1S 2,6 1;H4N3S 2,6 1; and H5N4F1S 2,6 1;

[0498] (b) comparing the value for the PSA glycoform level received in (a) with a reference value for the PSA glycoform; or comparing the aggressiveness score taking into account the PSA glycoform level received in (a) with a reference value for the aggressiveness score; and

[0499] (c) using the comparison in (b) to help determine whether the subject has an aggressive form of prostate cancer.

[0500] Other aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference. Aspects and embodiments of the present invention will now be discussed with reference to the following examples and accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0501] Figure 1 Schematic diagram of a PSA glycomics assay. Step 1 includes sample collection of a urine sample. Step 2 isolates PSA from the urine. Step 3 prepares the sample for analysis by reducing and alkylating the PSA followed by in-solution digestion (e.g., using trypsin). After sample preparation, the sample can be analyzed by capillary electrophoresis (step 4.A) followed by mass spectrometry for detection (step 4.B). After analysis, the data is collected and further processed (step 5).

[0502] Figure 2 AUC ROC of urinary compound 21 and serum fPSA% for distinguishing aggressive (Gleason ≥7) PCa from indolent PCa and BPH.

[0503] Figure 3 AUC ROC of the best urine 2-compound combination (compounds 3+7) and serum fPSA% for distinguishing aggressive PCa from indolent PCa and BPH.

[0504] Figure 4AUC ROC of the best urine 3-compound combination (compounds 4+7+monoantennary glycans) and serum fPSA% for distinguishing aggressive PCa from indolent PCa and BPH.

[0505] Figure 5 AUC ROC of the best urine 4-compound combination (compounds 2+9+13+22) and serum fPSA% for distinguishing aggressive PCa from indolent PCa and BPH.

[0506] Figure 6 .Major glycoforms with the same group characteristics (up or down). Structural glycosylation characteristics (e.g., sialylation, fucosylation, and branching type) are annotated in the left column. Structural descriptions are given in the right column under "Glycan Structure". "1" indicates the presence of a specific feature for a given glycan and "0" indicates the absence of a specific feature for a given glycoform.

[0507] Figure 7 .AUC ROC of the optimal ratio between up-regulated and down-regulated urine PSA glycostructures and serum fPSA% for distinguishing aggressive PCa from indolent PCa and BPH.

[0508] Figures 8 to 18 Depicted are exemplary structures of various PSA glycoforms (compounds) of the invention attached to a peptide (PEP). The right side represents the use of the SNFG (Symbol Nomenclature for Glycans) system (Ajit Varki et al., Symbol Nomenclature for Graphical Representations of Glycans, Glycobiology, Volume 25, Issue 12, December 2015, Pages 1323-1324, https: / / doi.org / 10.1093 / glycob / cwv091 and Sriram Neelamegham et al., The SNFG Discussion Group, Updates to the Symbol Nomenclature for Glycans guidelines, Glycobiology, Volume 29, Issue 9, September 2019, Pages 620-624, https: / / doi.org / 10.1093 / glycob / cwz045). The linkage type (2,3 or 2,6) of sialic acid is shown in Table 1A above.

[0509] Figure 8 – The structure of Exemplary Compound 2 is depicted.

[0510] Fig. 9 – The structure of exemplary compound 3 is depicted.

[0511] Fig.10 – The structure of exemplary compound 4 is depicted.

[0512] Fig.11 – The structure of exemplary compound 5 is depicted.

[0513] Fig.12 – The structure of exemplary compound 7 is depicted.

[0514] Fig.13 – The structure of exemplary compound 9 is depicted.

[0515] Fig.14 – The structure of exemplary compound 13 is depicted.

[0516] Fig.15 – The structure of exemplary compound 18 is depicted.

[0517] Fig.16 – The structure of exemplary compound 21 is depicted.

[0518] Fig.17 – The structure of exemplary compound 22 is depicted.

[0519] Fig.18 – The structure of exemplary compound 24 is depicted.

[0520] Examples

[0521] Example 1

[0522] 1.1 Abbreviations:

[0523] HAc Acetic acid

[0524] BGE background electrolyte

[0525] CE-ESI-MS Capillary electrophoresis-electrospray ionization-mass spectrometry using a sheathless porous sprayer

[0526] PSA Prostate-specific antigen

[0527] BPH Benign prostatic hyperplasia

[0528] LE Leading Electrolyte

[0529] AmAc ammonium acetate

[0530] PCa Prostate Cancer

[0531] RT Room temperature

[0532] ABC Ammonium Bicarbonate

[0533] FA Formic acid

[0534] PGA PSA glycomics assay

[0535] FUP Female Urine Mixture

[0536] DTT Dithiothreitol

[0537] IAA Iodoacetamide

[0538] Serum fPSA% The percentage of free PSA in serum to total PSA

[0539] 1.2 Materials

[0540] 1.2.1 Clinical samples

[0541] A total of 110 digital rectal examination (DRE) urine samples from 106 patients with elevated serum PSA concentrations in the "grey zone" (total PSA between 2 ng / ml and 10 ng / ml) were analyzed using an optimized PSA glycomics assay (PGA). This panel included four replicates for technical robustness assessment.

[0542] DRE urine samples obtained from a prospective multicenter study were analyzed. The sample panel consisted of urine from 33 benign controls (benign prostatic hyperplasia; BPH) and 73 PCa patients. Prostate cancer (PCa) samples were further divided into indolent PCa (Gleason score ≤ 6, n = 29) and aggressive PCa (Gleason score ≥ 7, n = 44). The total PSA serum values ​​of most PCa patients were between 2ng / ml and 10ng / ml, thus representing the gray zone population (the demographic data and clinical information of the sample panel are shown in Tables 2 and 3). The PGA method uses 1mL DRE urine.

[0543] All samples were diluted to 100 ng / mL PSA before the capture procedure unless the concentration was below this threshold (based on the total PSA Elecsys assay - Roche Diagnostics GmbH, Mannheim, Gemany). Dilutions were performed using a female urine pool (FUP) created by pooling urine samples from healthy female volunteers.

[0544] 1.2.2 Positive Control

[0545] A PSA-protein standard derived from human semen (obtained from Lee BioSolutions-St. Louis, MO) was used as a positive control. A positive control sample was created by adding 100 ng of the PSA-protein standard to the FUP.

[0546] 1.2.3 Negative Control FUP from urine samples obtained from healthy female volunteers were used as negative controls.

[0547] 1.2.4 System suitability samples

[0548] The tryptic digest of PSA-protein standard was used as a system suitability sample to test whether the analytical performance was as expected before analyzing the DRE urine sample. To this end, several aliquots containing 50ng PSA-protein standard and internal peptide standard were prepared (see Table 4), and then the protein was reduced, alkylated and trypsinized. After digestion, the samples were merged and redistributed into aliquots of the same amount (scheme see Kammeijer et al. Anal. Chem. 90, 4414-4421, 2018).

[0549] Table 2. Patient demographics stratified by PCa versus BPH

[0550]

[0551] Table 3 Patient demographics stratified by PCa aggressiveness.

[0552]

[0553] 1.3 Methods

[0554] 110 patient samples were randomly divided into six batches. Each batch included a positive control and a negative control.

[0555] 1.3.1 Anti-PSA beads IgG-M36

[0556] Biotinylated monoclonal IgG clone M36 anti-PSA antibody was obtained from Roche Diagnostics GmbH, Mannheim, Germany. 6 mg (3 mg / mL) of antibody solution was added to 600 μL of washed streptavidin beads (ThermoFischer) and incubated overnight at 4°C with continuous mixing. The next day, the beads were washed with 1xPBS to remove unbound antibodies. Non-specifically bound antibodies were removed by incubating the beads in 100 mM formic acid (FA) for 5 minutes. The pH was readjusted to 7 and the beads were stored at 4°C as a 50% slurry in 1xPBS containing 0.02% sodium azide (NaN3) as a preservative. Such beads can be used without prewashing.

[0557] 1.3.2PSA Capture

[0558] The samples were thawed, mixed manually and spun at 500 g for 1 min to precipitate and remove the precipitate. The supernatant was collected and used for further analysis and the samples were placed on ice. Dilutions were made to 100 ng / mL according to the urine PSA concentration and added to 1 mL with FUP. If the concentration was less than 100 ng / mL, the whole sample was used.

[0559] If enough sample was left, an additional 20 ng was drawn from each urine sample to generate a pooled sample. For all experimental steps, samples and reagents were kept on ice to keep the PSA as stable as possible before the capture procedure began.

[0560] A total of 250uL 5xPBS and 2μL 50% antibody-bead suspension (IgG-M36) were added to the sample and captured overnight at 4°C. Next, the beads were washed once with PBS (pH 7-8) and twice with ammonium bicarbonate (ABC) (pH 8). Prior to elution, an internal standard (Table 4) was added to the sample wells. PSA was eluted with 100mM FA (pH 2-3). The sample was dried after elution.

[0561] Table 4 : Synthetic peptides (internal standards) added to the samples before elution and their similarity to endogenous peptides.

[0562] Peptides Peptide sequence SEQ ID NO: Endogenous peptides LSEPAELTDAVK 1 Internal peptide standards LSEPAELTEAVK 2

[0563] 1.3.3 Digestion

[0564] Samples were digested as described by Kammeijer et al. (supra). In brief, the dried eluate of the captured PSA glycoprotein sample was reconstituted in 25 mM ammonium bicarbonate (ABC) buffer. Reduction was performed at 60°C for 30 min using dithiothreitol (DTT) at a final concentration of 2 mM. The samples were cooled at room temperature (RT) and sulfide alkylated using iodoacetamide (IAA) at RT in the dark for 30 min (final concentration of 6 mM). To ensure that the alkylation process was stopped, additional DTT was added (final concentration of 6 mM). For overnight digestion at 37°C, 0.15 ug porcine trypsin was added.

[0565] 1.3.4 Equipment

[0566] All capillary electrophoresis (CE) experiments were performed on a CESI 8000 system (SCIEX Separations, Framingham, MA) with 91-cm long bare fused capillaries, dynamic coated neutral capillaries, or static coated neutral capillaries (all with 30 μm inner diameter and 150 μm outer diameter). Prior to analysis, the capillaries were thoroughly flushed with 0.1 M NaOH (2.5 min), 0.1 M HCl (2.5 min), water (4 min), and background electrolyte (BGE) consisting of 10% acetic acid (HAc) (v / v, pH 2.3).

[0567] For analysis, an online pre-concentration step (e.g., transient isotachophoresis (t-ITP)) was used. Ammonium acetate (AmAc) was added to the sample (400 mM) before injection. AmAC served as the leading electrolyte. For all experiments, samples were injected at 25 psi for 24 seconds (equivalent to about 13.5% of the capillary volume) and then subjected to BGE plunger by applying 0.5 psi for 25 seconds (equivalent to about 0.3% of the capillary volume). Separation was performed by applying a voltage of 20 kV.

[0568] The CE system was coupled to a UHR-QqTOF maXis Impact HD MS (Bruker Daltonics) via a sheathless CE-ESI-MS interface from SCIEX. A capillary voltage between -1000 V and -1300 V was applied to ensure stable electrospray. All experiments were performed in positive ionization mode. The drying gas (nitrogen) flow rate and temperature were set to 1.5 L / min and 150°C, respectively. MS data were acquired between m / z 200 and 2200 with a spectrum acquisition rate of 1 Hz.

[0569] 1.3.5 Data Analysis

[0570] CE-ESI-MS data were analyzed using DataAnalysis (Bruker Daltonics). Prior to data analysis, all MS spectra were calibrated using the sodium adduct detected at the beginning of the electropherogram. Data were manually screened for endogenous peptides (Table 4) and spiked internal standard I (synthetic peptides in which one amino acid was substituted by the endogenous peptide, see Table 4). Extracted ion electropherograms (EIEs, smoothed with Gaussian fits) were acquired using a width of m / z ± 0.05 units using the first three isotopes of doubly and triply charged analytes.

[0571] 1.4 Results

[0572] 1.4.1 System Applicability

[0573] The observed peak areas (sum of CE-MS intensities in MS1) for endogenous peptides and spiked internal standard I for the system suitability standard revealed that the system performed well throughout the measurement for all samples (data not shown).

[0574] 1.4.2 Clinical evaluation of PSA glycans

[0575] Measurement of 110 clinical samples led to the identification of 26 N-glycopeptides (areas expressed as relative peak area [%], normalized to all identified glycoforms, summing up to 100%).

[0576] The areas of individual glycoforms were grouped according to the same glycosylation characteristics, such as fucosylation, monosialylation, disialylation, α2,3 sialylation, α2,6 sialylation, or sulfation (as shown in Table 1B and identified as "Summary" in Table 5) for univariate and multivariate biostatistical analysis to identify structures (biomarkers) or combinations of multiple structures (biomarker panels) that provide the best discrimination of aggressive PCa from indolent PCa and BPH. See Table 4 for a list of individual and combined glycan biomarkers.

[0577] Table 1B indicates which class / glycosylation characteristics a particular glycoform has (e.g., is it monoantennary, biantennary, fucosylated, has a2,3 sialylation, etc.). If a compound ID in Table 4 above is marked as Aggregate (Yes), it means that each member of that class (as shown in Table 1B) was measured and added together (e.g., Compound Sulfation = Compounds 23, 24, 25, and 26).

[0578] The clinical performance of urine glycoforms or glycosylation classes was compared with the efficacy of serum free PSA % in the same cohort (Elecsys serum free PSA % = free PSA / total PSA).

[0579] Biostatistical analysis was performed as follows:

[0580] Univariate analysis was based on: (1) p-value from Wilcoxon test, (2) 30% false discovery rate (FDR), and (3) biomarker performance as described by area under the receiver operating characteristic curve (AUC ROC).

[0581] Multivariate analyses included (1) ROC analysis for all linear combinations of 2, 3, and 4 marker panels (1× cross-validation) and (2) selection frequencies of combinations from 2× cross-validation (inner loop: feature selection, outer loop: performance estimation, 100 splits in the training and test sets in the outer loop).

[0582] In addition, according to the multivariate analysis, the best combinations were mostly in the direction of + / - (increased compounds and decreased compounds) or - / + (decreased compounds and increased compounds). Therefore, the best up-regulated compound group (compounds 2, 3, 4, 5) and the down-regulated compound group (compounds 7, 9, 18, 24; Figure 6 ) and estimated its clinical manifestation in the study population.

[0583] Table 5. Identified individual glycoforms and combined compositions are indicated in the summary column as "No" and "Yes", respectively. Combined composition = all glycoforms with the described characteristics according to Tables 1A and 1B; the combination of levels was achieved by building a simple mathematical sum.

[0584] Compound ID Glycan_Structure Summary Compound 1 <![CDATA[H5N2]]> no Compound 2 <![CDATA[H4N3S 2,61 ]]> no Compound 3 <![CDATA[H4N3F1S 2,61 ]]> no Compound 4 <![CDATA[H4N3F1S 2,31 ]]> no Compound 5 <![CDATA[H3N4F1S 2,61 ]]> no Compound 6 <![CDATA[H6N3S 2,61 ]]> no Compound 7 <![CDATA[H4N4F1S 2,61 ]]> no Compound 8 <![CDATA[H5N4S 2,61 ]]> no Compound 9 <![CDATA[H5N4F1S 2,61 ]]> no Compound 10 <![CDATA[H5N4F1S 2,31 ]]> no Compound 11 <![CDATA[H4N5F1S 2,61 ]]> no Compound 12 <![CDATA[H5N4S 2,62 ]]> no Compound 13 <![CDATA[H5N4S 2,31 S 2,61 ]]> no Compound 14 <![CDATA[H5N4S 2,32 ]]> no Compound 15 <![CDATA[H4N5S 2,62 ]]> no Compound 16 <![CDATA[H4N5S 2,31 S 2,61 ]]> no Compound 17 <![CDATA[H5N4F1S 2,62 ]]> no Compound 18 <![CDATA[H5N4F1S 2,31 S 2,61 ]]> no Compound 19 <![CDATA[H5N4F1S 2,32 ]]> no Compound 20 <![CDATA[H4N5F1S 2,62 ]]> no Compound 21 <![CDATA[H4N5F1S 2,31 S 2,61 ]]> no Compound 22 <![CDATA[H3N6F1S 2,62 ]]> no Compound 23 <h2 style=";text-align:left;direction:ltr"><![CDATA[H4N5S <h2 style=";text-align:left;direction:ltr"> 2,61 <h2 style=";text-align:left;direction:ltr"> (SO3)1]]><h2 style=";text-align:left;direction:ltr"> no Compound 24 <h2 style=";text-align:left;direction:ltr"><![CDATA[H4N5S <h2 style=";text-align:left;direction:ltr"> 2,31 <h2 style=";text-align:left;direction:ltr"> (SO3)1]]><h2 style=";text-align:left;direction:ltr"> no Compound 25 <h2 style=";text-align:left;direction:ltr"><![CDATA[H4N5F1S <h2 style=";text-align:left;direction:ltr"> 2,61 <h2 style=";text-align:left;direction:ltr"> (SO3)1]]><h2 style=";text-align:left;direction:ltr"> no Compound 26 <h2 style=";text-align:left;direction:ltr"><![CDATA[H4N5F1S <h2 style=";text-align:left;direction:ltr"> 2,31 <h2 style=";text-align:left;direction:ltr"> (SO3)1]]><h2 style=";text-align:left;direction:ltr"> no a2,3 sialylated compounds a2,3 sialylation yes a2,6 sialylated compounds a2,6 sialylation yes disialylated compounds Disialylation yes Fucosylated compounds Fucosylation yes LacdiNAc compounds LacdiNAc yes Sia-LacdiNAc compounds Sia-LacdiNAc yes High mannose polysaccharide compounds High mannose polysaccharide yes Hybrid polysaccharide compounds Hybrid Glycan yes Monoantennary compounds Single antenna yes Sulfated compounds Sulfation yes

[0585] 1.4.3 Results Univariate analysis

[0586] Univariate analysis of glycosylation signatures for all 26 different glycoforms and 10 combinations revealed good clinical performance (discriminatory power) of PSA glycoforms (at least three glycoforms). AUC ROC for discriminating aggressive PCa from indolent PCa and BPH was higher compared to serum fPSA%.

[0587] In particular, compound 21 with AUC 64.1, compound 2 with AUC 63.0, and compound 9 with AUC 62.0 performed better than serum fPSA% (AUC 61.8). See Table 6 for detailed compound structures, and see Table 6 for comparison of AUC ROC of compound 21 with serum free PSA% Figure 2 .

[0588] Table 6. Univariate performance of all individual glycoforms and combined PSA glycoform classes for discriminating aggressive PCa from indolent PCa and BPH is ranked by their AUC values. Direction indicates an increase (+) or decrease (-) in the intensity of a given glycoform or class in Gleason ≥7 PCa. fPSA%: serum free PSA%.

[0589] Compound ID Glycan_Structure Corrected p-value AUC Compound 21 <![CDATA[H4N5F1S 2,31 S 2,61 ]]> 2.75e-1 64.1 Compound 2 <![CDATA[H4N3S 2,61 ]]> 2.75e-1 63 Compound 9 <![CDATA[H5N4F1S 2,61 ]]> 2.75e-1 62 fPSA% 2.75e-1 61.8 Compound 18 <![CDATA[H5N4F1S 2,31 S 2,61 ]]> 2.75e-1 61.6 Compound 14 <![CDATA[H5N4S 2,32 ]]> 2.75e-1 60.7 Compound 11 <![CDATA[H4N5F1S 2,61 ]]> 2.75e-1 60.5 Compound 20 <![CDATA[H4N5F1S 2,62 ]]> 2.75e-1 60.3 Compound 19 <![CDATA[H5N4F1S 2,32 ]]> 2.75e-1 60.1 Compound 12 <![CDATA[H5N4S 2,62 ]]> 2.75e-1 59.9 Compound 22 <![CDATA[H3N6F1S 2,62 ]]> 2.75e-1 59.9 Sulfated compounds Sulfation 2.75e-1 59.2 Compound 24 <h2 style=";text-align:left;direction:ltr"><![CDATA[H4N5S <h2 style=";text-align:left;direction:ltr"> 2,31 <h2 style=";text-align:left;direction:ltr"> (SO3)1]]><h2 style=";text-align:left;direction:ltr"> 2.75e-1 59.1 Compound 3 <![CDATA[H4N3F1S 2,61 ]]> 2.75e-1 59.1 Compound 7 <![CDATA[H4N4F1S 2,61 ]]> 2.75e-1 59.1 a2,3 sialylated compounds a2,3 sialylation 2.76e-1 58.9 disialylated compounds Disialylation 2.76e-1 58.7 Compound 26 <h2 style=";text-align:left;direction:ltr"><![CDATA[H4N5F1S <h2 style=";text-align:left;direction:ltr"> 2,31 <h2 style=";text-align:left;direction:ltr"> (SO3)1]]><h2 style=";text-align:left;direction:ltr"> 2.76e-1 58.5 a2,6 sialylated compounds a2,6 sialylation 2.76e-1 58.4 Monoantennary compounds Single antenna 2.76e-1 58.4 Fucosylated compounds Fucosylation 2.82e-1 58.3 Compound 10 <![CDATA[H5N4F1S 2,31 ]]> 2.89e-1 58.1 LacdiNAc compounds LaCdiNAC 2.89e-1 58.1 Sia-LacdiNAc compounds Sia-LacdiNAc 2.92e-1 58

[0590] 1.4.4 Results Multivariate Analysis

[0591] In multivariate analysis combining 2, 3, or 4 compounds or groups of compounds, all glycoform combinations performed better in discriminating aggressive PCa from indolent PCa and BPH compared with serum fPSA% (Tables 7 to 9 and Figures 3 to 5Adding more compounds to the combination panel steadily increased panel performance, with an AUC of 69.8 for two structures (compounds 3+7); 73.0 for three structures (compounds 4+7+monoantennary); and 75.1 for the combination of four structures (compounds 2+9+13+22).

[0592] Table 7 .Multivariate performance of bivariate 2-compound combinations ranked according to their AUC values ​​for discriminating aggressive PCa from indolent PCa and BPH. fPSA%: serum free PSA%.

[0593]

[0594] Table 8. Multivariate The multivariate performance of the 3-compound combination was ranked according to their AUC values ​​to discriminate aggressive PCa from indolent PCa and BPH. fPSA%: serum free PSA%.

[0595]

[0596] Table 9. Multivariate The multivariate performance of the 4-compound combination was ranked according to their AUC values ​​to discriminate aggressive PCa from indolent PCa and BPH. fPSA%: serum free PSA%.

[0597]

[0598] 1.4.5 Results - Ratio Analysis

[0599] Since the selected combinations of two markers were mostly + / - or - / + combinations and the coefficients in the multivariate model (where logistic regression with log-transformed markers was used) had comparable absolute values, the identity c log(M1)-clog(M ! ) = c log (M1 / M2) indicates the utility of the marker ratio.

[0600] Figure 6 The strongest up- and down-regulated features are shown.

[0601] Biostatistical analysis showed that there was a significant benefit in clinical performance via multivariate combination by including artificially combined features (group up, group down) and calculating their ratios (Table 10 and Figure 7 ).

[0602] Table 10.The performance of the ratio between the major up-regulated and down-regulated compounds was ranked according to their AUC values ​​for distinguishing aggressive PCa from indolent PCa and BPH.fPSA%: serum free PSA%; Rat.: ratio; Comp.Art. = artificial combined levels of the specified compounds (combination was achieved by establishing the sum of the specified compound levels).

[0603] Compound ID Corrected p-value AUC Ratio of Comp.Art.2.3.5 to Comp.Art.24.7.9 4.62e-3 73 Ratio of Comp.Art.2.3 to Comp.Art.7.9 4.62e-3 73 Ratio of Comp.Art.3.5 to Comp.Art.24.7.9 4.62e-3 72.8 Ratio of Comp.Art.2.3.5 to Comp.Art.7.9 4.62e-3 72.7 Ratio of Comp.Art.2.3 to Compound 7 4.62e-3 72.7 Ratio of Comp.Art.3.5 to Comp.Art.7.9 4.62e-3 72.5 Ratio of Comp.Art.2.3 to Compound 9 4.62e-3 72.4 Ratio of Comp.Art.3.5 to Comp.Art.24.9 4.62e-3 72.4 Ratio of Comp.Art.2.3 to Comp.Art.24.7.9 4.62e-3 72.3 Ratio of Comp.Art.7.9 to Compound 3 4.62e-3 72.3 The ratio of compound 3 to compound 9 4.62e-3 72.2 Ratio of Comp.Art.2.3.5 to Compound 7 4.62e-3 72.2 Ratio of Comp.Art.2.3.5 to Compound 9 4.62e-3 72.2 Ratio of Comp.Art.3.5 to Compound 9 4.62e-3 72.1 Ratio of Comp.Art.24.7.9 to Compound 3 4.88e-3 71.9 Ratio of Comp.Art.2.3.5 to Comp.Art.24.9 5.03e-3 71.5 Ratio of Comp.Art.2.3 to Comp.Art.18.24.7.9 5.03e-3 71.5 Ratio of Comp.Art.2.3 to Comp.Art.24.9 5.03e-3 71.5 Ratio of Comp.Art.2.3.5 to Comp.Art.18.24.7.9 5.03e-3 71.4 Ratio of Comp.Art.2.3.5 to Comp.Art.18.7.9 5.03e-3 71.4 fPSA% 1.04e-1 61.8

[0604] Interestingly, all major down-regulated structures (compounds 2, 3, 4, 5) represented complex monoantennary N-glycans, whereas the up-regulated group (compounds 7, 9, 18, and 24) contained specific complex biantennary, sialylated, and fucosylated N-glycans. Therefore, it can be concluded that the ratio between monoantennary and biantennary PSA glycoforms is a novel marker (signature) for improved differentiation of aggressive PCa from its indolent forms and benign controls.

[0605] 1.5 Conclusion

[0606] CE-MS-based sugar profiling of urine PSA glycoforms revealed several novel structures and combinations of structures that performed clinically better than serum fPSA% in distinguishing aggressive from indolent prostate cancer:

[0607] In the univariate setting: AUCs of the three glycoforms were greater than serum fPSA%

[0608] In the multivariate 2-marker setting: approximately 6% improvement over univariate models

[0609] In the multivariate 3-marker setting: approximately 10% improvement over univariate models

[0610] In the multivariate 3-marker setting: approximately 12% improvement over univariate models, approximately 5% to 10% improvement over Beckman Prostate Health Index (PHI) (serum)

[0611] - Multivariate combination of artificially combined features (up-regulated group, down-regulated group) and ratios yielded a significant benefit on clinical performance, with an improvement of approximately 10% over univariate models and approximately 5% to 10% over Beckman PHI (serum).

Claims

1. A method for assisting in determining whether a subject has an aggressive form of prostate cancer, the method comprising: (a) determining the level of at least one monoantennary PSA glycoform and the level of at least one biantennary PSA glycoform in a biological fluid sample from the subject; (b) calculating an aggressiveness score for the subject based on the level determined in (a); (c) comparing the aggressiveness score of the subject in (b) with a reference value for the aggressiveness score; as well as (d) using the comparison in (c) to help determine whether the subject has an aggressive form of prostate cancer.

2. The method according to claim 1, wherein step (a) comprises: (i) isolating PSA protein from a biological fluid sample from the subject; (ii) treating the isolated PSA protein with a protease such as trypsin or Arg-C (clostripain); (iii) determining that two or more of the samples contain N 69 The level of each of the glycopeptide forms of 69 At least one of the glycopeptide forms of 69 At least one of the glycopeptide forms is a biantennary glycoform.

3. The method according to any one of claims 1 or 2, wherein the at least one monoantennary PSA glycoform is selected from the group consisting of: H4N3S 2,6 1;H4N3F1S 2,6 1;H4N3F1S 2,3 1: and H3N4F1S 2,6 1.

4. The method according to any one of claims 1 to 3, wherein the at least one biantennary PSA glycoform is selected from the group consisting of: H4N4F1S 2,6 1;H5N4F1S 2,6 1;H5N4F1S 2,3 1;H4N5F1S 2,6 1; H5N4S 2,3 1S 2,6 1;H4N5S 2,3 1S 2,6 1;H4N5F1S 2,3 1S 2,6 1;H4N5S 2,3 1(SO3)1; and H4N5F1S 2,6 1(SO3)1.

5. The method according to any one of claims 1 to 4, wherein the aggressiveness score comprises or consists of: The ratio of the level of the at least one biantennary PSA glycoform relative to the at least one monoantennary PSA glycoform in a sample from a subject, or the ratio of the level of the at least one monoantennary PSA glycoform relative to the at least one biantennary PSA glycoform in a sample from a subject.

6. The method according to any one of the preceding claims, wherein the PSA glycoform used or determined in the method of the invention comprises a PSA glycoform selected from the group consisting of: (i)H4N3F1S 2,6 1 and H4N4F1S 2,6 1; (ii)H4N3F1S 2,6 1 and H5N4F1S 2,6 1; (iii)H4N3S 2,6 1 and H4N5S 2,3 1(SO3)1; (iv)H4N3S 2,6 1 and H5N4F1S 2,3 1S 2,6 1; (v)H4N3S 2,6 1 and H4N4F1S 2,6 1; (vi)H4N3F1S 2,6 1 and H5N4F1S2,31S 2,6 1; (vii) H4N3S2, 61 and H4N5F1S 2,3 1S 2,6 1; (viii)H4N3S 2,6 1 and H4N5F1S 2,6 1; and (ix)H3N4F1S 2,6 1 and H4N5F1S2,31S 2,6 1.

7. The method according to any one of claims 1 to 5, wherein the PSA glycoform used or determined in the method of the present invention comprises a PSA glycoform selected from the group consisting of: a.H4N4F1S 2,6 1 and a combination of monoantennary glycoforms; b.H4N3S 2,6 1 and a combination of monoantennary glycoforms; c.H4N3S 2,6 1 and a2.

3. Combination of sialylated glycoforms; d.H4N3S 2,6 1 and a2.

6. Combination of sialylated glycoforms; e.H5N4F1S 2,3 1S 2,6 1 and a combination of monoantennary glycoforms; f.H5N4F1S 2,3 1 and a combination of monoantennary glycoforms; g.a2.

3. Combinations of sialylated glycoforms and monoantennary glycoforms; h.H4N5F1S 2,3 1S 2,6 1 and a combination of monoantennary glycoforms; and i.H4N3F1S 2,3 1 and a combination of monoantennary glycoforms.

8. The method according to any one of the preceding claims, wherein the subject is a mammal, such as a male human, and / or wherein the biological fluid sample is selected from: blood, serum, plasma, semen, prostatic fluid, and urine such as a digital rectal examination (DRE) urine sample.

9. The method according to any one of the preceding claims, wherein the subject is preselected based on having prostate enlargement or based on the level of total serum PSA, optionally wherein the level of total serum PSA in the subject is between about 2 ng / ml and 10 ng / ml.

10. The method according to any one of the preceding claims, wherein PSA protein in the biological fluid sample of the subject is separated from the sample, optionally by using a capture binding partner such as an anti-PSA antibody.

11. The method of claim 10, wherein the isolated PSA protein is treated with a protease to produce a protein comprising N 69 of glycopeptides.

12. The method according to any one of the preceding claims, wherein the level of each measured PSA glycoform is determined by mass spectrometry such as CE-ESI-MS or LC-ESI-MS( / MS) or MALDI-TOF MS.

13. The method according to any one of claims 1 to 12, wherein the reference value for the aggressiveness score has been determined from samples of at least one reference population, the reference population comprising: aggressive PCa subjects; and subjects not suffering from aggressive PCa, such as patients suffering from prostatitis, BPH or indolent PCa, optionally wherein the disease state is known.

14. A kit for use in a method according to any one of embodiments 1 to 13, the kit comprising a scoring system having reference values ​​or ratios of PSA glycoforms indicative of aggressive PCa, and optionally (i) instructions for use, and / or (ii) a PSA binding partner, such as a monoclonal antibody, optionally wherein the PSA binding partner is immobilized on a solid surface such as beads.

15. A computer-implemented method for assisting in determining whether a subject has an aggressive form of prostate cancer, the computer-implemented method comprising the steps of: (a) receiving a value for the level of a first monoantennary PSA glycoform in a biological fluid sample of the subject; (b) receiving a value for the level of a first biantennary PSA glycoform in the biological fluid sample of the subject; (c) calculating an aggressiveness score for the subject based on the levels received in (a) and (b); (d) comparing the aggressiveness score of the subject in (c) with a reference value for the aggressiveness score; as well as (e) using the comparison in (d) to help determine whether the subject has an aggressive form of prostate cancer.